Exhibit 99
Pfizer Reports Full-Year 2023 Results and Reaffirms Full-Year 2024 Financial Guidance
•2023 Sets Stage for Future Growth Potential: Completed Seagen Acquisition, Creating World-Class Oncology Organization; Launched Significant Number of New Products and Indications; and Realigned Commercial Organization to Improve Focus, Speed and Execution
▪Full-Year 2023 Revenues of $58.5 Billion
–Expected Decline in Comirnaty(1) and Paxlovid Revenues Drove 41% Operational Decrease in Year-Over-Year Revenues
–Excluding Contributions from Comirnaty(1) and Paxlovid, Revenues Grew 7% Operationally, Driven by a Combination of New Product and Indication Launches and In-Line Product Growth
▪Full-Year 2023 Reported(2) Diluted EPS of $0.37, Down 93% Year-Over-Year, and Adjusted(3) Diluted EPS of $1.84, Down 72% Year-Over-Year, Significantly Impacted by One-Time Events(4)
▪Fourth-Quarter 2023 Revenues of $14.2 Billion
–Expected Decline in Comirnaty(1) and Paxlovid Revenues Drove 42% Operational Decrease in Fourth-Quarter Revenues
–Excluding Contributions from Comirnaty(1) and Paxlovid, Revenues Grew 8% Operationally
▪Fourth-Quarter 2023 Reported(2) Diluted Loss Per Share (LPS) of $(0.60) and Adjusted(3) Diluted EPS of $0.10, Significantly Impacted by One-Time Events(4)
▪On Track to Deliver at Least $4 Billion in Annual Net Cost Savings by End of 2024 from Previously Announced Cost Realignment Program
▪Reaffirms Full-Year 2024 Guidance(5) Provided on December 13, 2023, of Revenues of $58.5 to $61.5 Billion and Adjusted(3) Diluted EPS of $2.05 to $2.25
NEW YORK, Tuesday, January 30, 2024 — Pfizer Inc. (NYSE: PFE) reported financial results for fourth quarter and full-year 2023 and reaffirmed its 2024 financial guidance(5) provided on December 13, 2023.
The fourth-quarter 2023 earnings presentation and accompanying prepared remarks from management as well as the quarterly update to Pfizer’s R&D pipeline can be found at www.pfizer.com.
EXECUTIVE COMMENTARY
Dr. Albert Bourla, Chairman and Chief Executive Officer, stated: “We are encouraged by the strong performance of our non-COVID products in the fourth quarter of 2023, including significant contributions from new launches and robust year-over-year growth for several key in-line brands. In 2023, Pfizer received a record number of nine new molecular entity approvals by the U.S. Food and Drug Administration (FDA)—medicines and vaccines that are expected to favorably impact Pfizer’s performance in the coming years.
- 1 -
“In addition, we completed the acquisition of Seagen in December 2023, a critical step toward our goal to achieve world-class Oncology leadership. With the combined strength of Pfizer’s and Seagen’s talent, portfolios and platforms, we believe we have the potential to transform outcomes by delivering cancer medicines that help patients live better and longer lives. We look forward to sharing the vision of the new Pfizer Oncology Division at our announced Oncology Innovation Day on Thursday, February 29.
“We are entering 2024 with a solid foundation. We believe our commitment to execution, maximizing the performance of our new products, and delivering the next wave of pipeline innovation will fuel Pfizer’s growth and make a difference in the lives of patients everywhere.”
David Denton, Chief Financial Officer and Executive Vice President, stated: “We are pleased with the strong 8% operational revenue growth of Pfizer’s non-COVID products in the fourth quarter of 2023, achieving our full-year 2023 non-COVID operational revenue growth target of 6% to 8%. In addition, we are on track to deliver at least $4.0 billion in annual net cost savings by the end of 2024 from our cost realignment program. We are prepared to execute our commercial strategy to drive continued growth from our newly launched and acquired products, and to deliver on our targeted cost savings that we expect will expand our operating margins in 2024 and beyond.”
Results for fourth-quarter and full-year 2023 and 2022(6) are summarized below.
OVERALL RESULTS
| ($ in millions, except per share amounts) | Fourth-Quarter | Full-Year | ||||||||||||||||||
| 2023 | 2022 | Change | 2023 | 2022 | Change | |||||||||||||||
| Revenues | $ 14,249 | $ 24,290 | (41%) | $ 58,496 | $ 100,330 | (42%) | ||||||||||||||
Reported(2) Net Income/(Loss) | (3,369) | 4,995 | * | 2,119 | 31,372 | (93%) | ||||||||||||||
Reported(2) Diluted EPS/(LPS) | (0.60) | 0.87 | * | 0.37 | 5.47 | (93%) | ||||||||||||||
Adjusted(3) Income | 593 | 6,551 | (91%) | 10,501 | 37,717 | (72%) | ||||||||||||||
Adjusted(3) Diluted EPS | 0.10 | 1.14 | (91%) | 1.84 | 6.58 | (72%) | ||||||||||||||
* Indicates calculation not meaningful.
REVENUES
| ($ in millions) | Fourth-Quarter | Full-Year | |||||||||||||||||||||||||||
| 2023 | 2022 | % Change | 2023 | 2022 | % Change | ||||||||||||||||||||||||
| Total | Oper. | Total | Oper. | ||||||||||||||||||||||||||
Global Biopharmaceuticals Business (Biopharma) | $ 13,867 | $ 23,922 | (42%) | (42%) | $ 57,186 | $ 98,988 | (42%) | (41%) | |||||||||||||||||||||
Primary Care | 6,986 | 17,348 | (60%) | (60%) | 30,589 | 73,023 | (58%) | (57%) | |||||||||||||||||||||
Specialty Care | 3,949 | 3,566 | 11% | 11% | 14,970 | 13,833 | 8% | 11% | |||||||||||||||||||||
Oncology | 2,932 | 3,007 | (3%) | (2%) | 11,627 | 12,132 | (4%) | (3%) | |||||||||||||||||||||
| Business Innovation | $ 382 | $ 368 | 4% | 2% | $ 1,310 | $ 1,342 | (2%) | (2%) | |||||||||||||||||||||
| TOTAL REVENUES | $ 14,249 | $ 24,290 | (41%) | (42%) | $ 58,496 | $ 100,330 | (42%) | (41%) | |||||||||||||||||||||
- 2 -
In the first quarter of 2023, Pfizer established an operating segment, Business Innovation, that includes Pfizer CentreOne (PC1), the company’s global contract development and manufacturing organization and a leading supplier of specialty active pharmaceutical ingredients; and Pfizer Ignite, an offering that provides strategic guidance and end-to-end R&D services to select innovative biotech companies that align with Pfizer’s R&D focus areas. The prior period has been revised to conform to the current period presentation.
Some amounts in this press release may not add due to rounding. All percentages have been calculated using unrounded amounts. References to operational variances pertain to period-over-period changes that exclude the impact of foreign exchange rates(7).
CAPITAL ALLOCATION
During full-year 2023, Pfizer deployed its capital in a variety of ways, which primarily include the following two categories:
▪Reinvesting capital into initiatives intended to enhance the future growth prospects of the company, including:
•$10.7 billion invested in internal research and development projects, and
•Approximately $43.8 billion invested in completed business development transactions, net of cash acquired, including approximately $43 billion for the acquisition of Seagen Inc.
▪Returning capital directly to shareholders through $9.2 billion of cash dividends, or $1.64 per share of common stock.
No share repurchases were completed in 2023. As of January 30, 2024, Pfizer’s remaining share repurchase authorization is $3.3 billion. Current financial guidance does not anticipate any share repurchases in 2024.
For the fourth quarter of 2023, basic weighted-average shares outstanding of 5,647 million were used to calculate Reported(2) LPS and diluted weighted-average shares outstanding of 5,692 million were used to calculate Adjusted(3) diluted EPS.
2024 FINANCIAL GUIDANCE(5)
Pfizer expects full-year 2024 revenues(2) to be in the range of $58.5 to $61.5 billion, which includes approximately $8 billion in anticipated revenues for Comirnaty(1) and Paxlovid (approximately $5 billion and $3 billion, respectively), approximately $3.1 billion in anticipated revenues from Seagen and approximately $1 billion related to the reclassification of Pfizer’s royalty income from Other (Income)/Deductions into the Revenue line.
- 3 -
Including the contribution from Seagen and excluding revenues from Comirnaty(1) and Paxlovid, Pfizer expects to achieve full-year 2024 operational revenue growth of 8% to 10% compared to 2023 revenues. Excluding revenues from Comirnaty(1) and Paxlovid and the expected contribution from Seagen, Pfizer expects to achieve full-year 2024 operational revenue growth of 3% to 5% compared to 2023 revenues. While the company will begin reporting royalty income in the revenue line in 2024, for growth rate purposes, the company has included royalty income in revenues in both 2023 and 2024. Consequently, there is no operational revenue growth attributable to the reclassification of royalty income.
Including the impact of Seagen, Pfizer anticipates full-year 2024 Adjusted(3) SI&A expenses to be in the range of $13.8 billion to $14.8 billion and full-year 2024 Adjusted(3) R&D expenses to be in the range of $11.0 to $12.0 billion. Consequently, total 2024 Adjusted(3) SI&A and R&D expenses are expected to be in the range of $24.8 to $26.8 billion. This range reflects an anticipated decline of approximately $4 billion by the end of 2024 versus the midpoint of Pfizer’s SI&A and R&D expense guidance provided on August 1, 2023, solely driven by Pfizer’s cost realignment program, partially offset by the impact of Seagen.
2024 Adjusted(3) diluted EPS is anticipated to be in a range of $2.05 to $2.25, which primarily reflects:
▪Expected operational revenue growth of 8% to 10% compared to 2023 revenues, excluding Comirnaty(1) and Paxlovid and including the impact of Seagen; and
▪Anticipated operating margin improvement from the company’s cost realignment activities; partially offset by
▪An expected $0.40 dilutive impact related to the Seagen acquisition, which is predominantly driven by costs to finance the transaction.
Pfizer’s 2024 financial guidance(5), including the impact of certain significant factors, is presented below.
2023 Results | 2024 Legacy Pfizer Guidance | Anticipated Impact of Royalty Income Reclass Included in 2024 Guidance | Anticipated 2024 Seagen Impact Included in 2024 Guidance | 2024 Financial Guidance(5) | |||||||||||||
Revenues ($ in billions) | $58.5 | $54.5 to $57.5 | $1.0 | $3.1 | $58.5 to $61.5 | ||||||||||||
Adjusted(3) SI&A Expenses ($ in billions) | $14.4 | $13.8 to $14.8 | |||||||||||||||
Adjusted(3) R&D Expenses ($ in billions) | $10.6 | $11.0 to $12.0 | |||||||||||||||
Effective Tax Rate on Adjusted(3) Income | 9.0% | ~15.0% | |||||||||||||||
Adjusted(3) Diluted EPS | $1.84 | $2.45 to $2.65 | - | $(0.40) | $2.05 to $2.25 | ||||||||||||
Financial guidance for Adjusted(3) diluted EPS is calculated using approximately 5.75 billion weighted average shares outstanding and assumes no share repurchases in 2024.
- 4 -
QUARTERLY FINANCIAL HIGHLIGHTS (Fourth-Quarter 2023 vs. Fourth-Quarter 2022)
Fourth-quarter 2023 revenues totaled $14.2 billion, a decrease of $10.0 billion, or 41%, compared to the prior-year quarter, reflecting an operational decline of $10.1 billion, or 42%, primarily due to a significant decrease in Comirnaty(1) and Paxlovid revenues globally, as well as a de minimis impact of foreign exchange. Excluding contributions from Comirnaty(1) and Paxlovid, company revenues grew $934 million, or 8%, operationally.
Fourth-quarter 2023 Comirnaty(1) revenues declined $6.1 billion, or 54%, operationally compared with the prior-year quarter, largely driven by lower U.S. government contracted deliveries following the transition to traditional U.S. commercial market sales, which began in September 2023, and by lower contracted deliveries and demand in international markets.
Fourth-quarter 2023 Paxlovid revenues declined $5.0 billion, to $(3.1) billion, compared with the prior-year quarter, primarily driven by a non-cash revenue reversal of $3.5 billion recorded in the fourth quarter of 2023, of which a portion was associated with sales recorded in 2022, related to the expected return of an estimated 6.5 million treatment courses of Emergency Use Authorization (EUA)-labeled U.S. government inventory; partially offset by sales under traditional commercial markets following transition, primarily in the U.S.
Excluding contributions from Comirnaty(1) and Paxlovid, fourth-quarter 2023 operational revenue growth was primarily driven by:
▪Abrysvo, which contributed $515 million in global revenues, driven primarily by launch of the older adult indication in the U.S. in July 2023;
▪Vyndaqel family (Vyndaqel, Vyndamax, Vynmac) globally, up 39% operationally, driven largely by continued strong uptake of the transthyretin amyloid cardiomyopathy (ATTR-CM) indication, primarily in the U.S. and developed Europe; and
▪Eliquis globally, up 9% operationally, driven primarily by continued oral anti-coagulant adoption and market share gains in the non-valvular atrial fibrillation indication in the U.S. and certain markets in Europe, partially offset by declines due to loss of exclusivity and generic competition in certain international markets;
partially offset primarily by lower revenues for:
▪Ibrance globally, down 13% operationally, driven primarily by lower demand globally due to competitive pressure and lower clinical trial purchases in certain international markets; and
▪Prevnar family (Prevnar 13 & 20) globally, down 7% operationally, driven primarily by the pediatric indication in emerging markets due to lower demand and unfavorable timing of customer orders.
- 5 -
GAAP Reported(2) Statement of Operations Highlights
SELECTED REPORTED(2) COSTS AND EXPENSES
| ($ in millions) | Fourth-Quarter | Full-Year | ||||||||||||||||||||||||||||||
| 2023 | 2022 | % Change | 2023 | 2022 | % Change | |||||||||||||||||||||||||||
| Total | Oper. | Total | Oper. | |||||||||||||||||||||||||||||
Cost of Sales(2) | $ 7,562 | $ 9,648 | (22%) | (24%) | $ 24,954 | $ 34,344 | (27%) | (29%) | ||||||||||||||||||||||||
Percent of Revenues | 53.1 | % | 39.7 | % | N/A | N/A | 42.7 | % | 34.2 | % | N/A | N/A | ||||||||||||||||||||
SI&A Expenses(2) | 4,575 | 4,644 | (1%) | (2%) | 14,771 | 13,677 | 8% | 9% | ||||||||||||||||||||||||
R&D Expenses(2) | 2,815 | 3,615 | (22%) | (22%) | 10,679 | 11,428 | (7%) | (6%) | ||||||||||||||||||||||||
Acquired IPR&D Expenses(2) | 73 | 73 | — | — | 194 | 953 | (80%) | (80%) | ||||||||||||||||||||||||
Other (Income)/Deductions––net(2) | (480) | (846) | (43%) | (51%) | (835) | 217 | * | * | ||||||||||||||||||||||||
Effective Tax Rate on Reported(2) Income/(Loss) | 19.2 | % | 4.4 | % | (105.4 | %) | 9.6 | % | ||||||||||||||||||||||||
* Indicates calculation not meaningful.
Fourth-quarter 2023 Cost of Sales(2) as a percentage of revenues increased by 13.4 percentage points compared with the prior-year quarter, driven primarily by the $3.5 billion non-cash Paxlovid revenue reversal; unfavorable changes in sales mix, primarily due to lower sales of Paxlovid and Comirnaty(1); and the unfavorable impact of foreign exchange.
Fourth-quarter 2023 SI&A Expenses(2) decreased 2% operationally compared with the prior-year quarter, driven primarily by a decrease in marketing and promotional expenses for Paxlovid, a lower provision for U.S. healthcare reform fees related to Paxlovid and Comirnaty(1), and lower compensation-related expenses, partially offset by increases in marketing and promotional expenses, including those related to recently launched and acquired products, as well as increased investments to build new internal marketing capabilities.
Fourth-quarter 2023 R&D Expenses(2) decreased 22% operationally compared with the prior-year quarter, driven primarily by lower compensation-related expenses, as well as by lower spending across (i) vaccine programs, (ii) certain acquired assets and (iii) for ongoing rare disease programs.
The unfavorable period-over-period change in Other income—net(2) of $366 million for the fourth quarter of 2023, compared to the fourth quarter of 2022, was driven primarily by higher intangible asset impairment charges, partially offset by an increase in net gains on equity securities.
Pfizer’s positive effective tax rate for the fourth quarter of 2023 reflects a tax benefit on a pre-tax Reported(2) loss and includes changes in the jurisdictional mix of earnings and the resolution of uncertain tax positions in various markets.
- 6 -
Adjusted(3) Statement of Operations Highlights
SELECTED ADJUSTED(3) COSTS AND EXPENSES
| ($ in millions) | Fourth-Quarter | Full-Year | ||||||||||||||||||||||||||||||
| 2023 | 2022 | % Change | 2023 | 2022 | % Change | |||||||||||||||||||||||||||
| Total | Oper. | Total | Oper. | |||||||||||||||||||||||||||||
Adjusted(3) Cost of Sales | $ 7,265 | $ 9,475 | (23 | %) | (26 | %) | $ 23,988 | $ 34,096 | (30%) | (31%) | ||||||||||||||||||||||
| Percent of Revenues | 51.0 | % | 39.0 | % | N/A | N/A | 41.0 | % | 34.0 | % | N/A | N/A | ||||||||||||||||||||
Adjusted(3) SI&A Expenses | 4,471 | 4,414 | 1 | % | 1 | % | 14,446 | 13,049 | 11% | 12% | ||||||||||||||||||||||
Adjusted(3) R&D Expenses | 2,770 | 3,610 | (23 | %) | (24 | %) | 10,568 | 11,409 | (7%) | (7%) | ||||||||||||||||||||||
Adjusted(3) Other (Income)/Deductions––net | (815) | (656) | 24 | % | 14 | % | (2,281) | (1,954) | 17% | 8% | ||||||||||||||||||||||
Effective Tax Rate on Adjusted(3) Income/(Loss) | (24.0%) | 11.1 | % | 9.0 | % | 11.7 | % | |||||||||||||||||||||||||
Reconciliations of certain Reported(2) to non-GAAP Adjusted(3) financial measures and associated footnotes can be found in the financial tables section of this press release.
FULL-YEAR REVENUE SUMMARY (Full-Year 2023 vs. Full-Year 2022)
Full-year 2023 revenues totaled $58.5 billion, a decrease of $41.8 billion, or 42%, compared to full-year 2022, reflecting an operational decline of $40.8 billion, or 41%, and an unfavorable impact of foreign exchange of $1.0 billion, or 1%. Excluding contributions from Comirnaty(1) and Paxlovid, revenues for the full-year grew 7% operationally.
The operational revenue decline compared to the prior year was driven primarily by significantly lower global revenues for Comirnaty(1) and Paxlovid and, to a much lesser extent, lower revenues for Ibrance, partially offset by an increase in revenues from Nurtec ODT/Vydura and Oxbryta, which were acquired in the fourth quarter of 2022; revenues from Abrysvo, primarily driven by the launch of the older adult indication in the U.S.; and continued growth from the Vyndaqel family and Eliquis.
RECENT NOTABLE DEVELOPMENTS (Since October 31, 2023)
Product Developments
▪Elrexfio (elranatamab-bcmm) – In December 2023, Pfizer announced the European Commission (EC) granted conditional marketing authorization for Elrexfio for the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least three prior therapies, including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 antibody and have demonstrated disease progression on the last therapy.
▪Padcev (enfortumab vedotin-ejfv)
- 7 -
•In January 2024, Pfizer and Astellas Pharma Inc. (Astellas) announced that the European Medicines Agency (EMA) validated for review a Type II variation application for Padcev, an antibody-drug conjugate (ADC), with Keytruda(8) (pembrolizumab, a PD-1 inhibitor) as a combination therapy for the first-line treatment of adult patients with previously untreated locally advanced or metastatic urothelial cancer (la/mUC). The EMA’s Committee for Medicinal Products for Human Use (CHMP), and subsequently the EC, are expected to share their opinions and decisions on the Type II variation application in calendar year 2024.
•In December 2023, Pfizer and Astellas announced that the FDA approved Padcev with Keytruda(8) for the treatment of adult patients with la/mUC based on the results from the Phase 3 EV-302 clinical trial. This combination is the first approved to offer an alternative to platinum-containing chemotherapy, the current standard of care in first-line la/mUC.
▪Prevnar 20 (20-valent pneumococcal conjugate vaccine) – In January 2024, Pfizer announced the CHMP of the EMA adopted a positive opinion, recommending the granting of a marketing authorization for its 20-valent pneumococcal conjugate vaccine candidate for active immunization for the prevention of invasive disease, pneumonia and acute otitis media caused by Streptococcus pneumoniae in infants, children and adolescents from 6 weeks to less than 18 years of age. The CHMP’s positive opinion will now be reviewed by the EC to decide whether to approve the vaccine. This decision is expected in the coming weeks and will apply to all 27 European Union (EU) member states plus Iceland, Liechtenstein and Norway.
▪Talzenna (talazoparib) – In January 2024, Pfizer announced that the EC approved Talzenna, an oral poly ADP-ribose polymerase (PARP) inhibitor, in combination with Xtandi (enzalutamide), for the treatment of adult patients with metastatic castration-resistant prostate cancer (mCRPC) in whom chemotherapy is not clinically indicated. With this approval, Talzenna is now the first and only PARP inhibitor licensed in the EU for use with Xtandi for patients with mCRPC, with or without gene mutations. The approval is valid in all 27 EU member states plus Iceland, Liechtenstein and Norway.
▪Tivdak (tisotumab vedotin-tftv) – In January 2024, Pfizer and Genmab A/S announced the FDA accepted the supplemental Biologics License Application (sBLA) seeking to convert the accelerated approval of Tivdak, an ADC, to full approval, for the treatment of patients with recurrent or metastatic cervical cancer with disease progression on or after first-line therapy. The sBLA is supported by efficacy and safety data from the global, randomized, Phase 3 innovaTV 301 trial. The application was granted Priority Review with a Prescription Drug User Fee Act (PDUFA) goal date of May 9, 2024.
▪Velsipity (etrasimod) – In December 2023, Pfizer announced the EMA’s CHMP adopted a positive opinion for Velsipity, an oral, once-daily, selective sphingosine-1-phosphate (S1P) receptor modulator for the treatment of patients 16 years of age and older with moderately to severely active ulcerative colitis (UC) who
- 8 -
have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biological agent. The EC will review the CHMP recommendation and is expected to make a final decision in the coming months.
▪Xtandi (enzalutamide) – In November 2023, Astellas and Pfizer announced the FDA approved a supplemental New Drug Application (sNDA) for Xtandi following FDA expedited development and review programs (Priority Review designation, Fast Track designation, Real-time Oncology Review), based on results from the Phase 3 EMBARK trial. With this approval, Xtandi becomes the first and only androgen receptor signaling inhibitor approved by the FDA for the treatment of patients with nonmetastatic castration-sensitive prostate cancer (nmCSPC) with biochemical recurrence at high risk for metastasis (high-risk BCR). Patients with nmCSPC with high-risk BCR may be treated with Xtandi with or without a gonadotropin-releasing hormone (GnRH) analog therapy.
Pipeline Developments
A comprehensive update of Pfizer’s development pipeline was published today and is now available at www.pfizer.com/science/drug-product-pipeline. It includes an overview of Pfizer’s research and a list of compounds in development with targeted indication and phase of development, as well as mechanism of action for some candidates in Phase 1 and all candidates from Phase 2 through registration.
▪Danuglipron – In December 2023, Pfizer announced topline data from the Phase 2b clinical trial investigating its oral glucagon-like peptide-1 receptor agonist (GLP-1RA) candidate danuglipron in adults with obesity and without type 2 diabetes. The study met its primary endpoint demonstrating statistically significant change in body weight from baseline. While the most common adverse events were mild and gastrointestinal in nature consistent with the mechanism, high rates were observed. High discontinuation rates were seen across all doses compared to placebo. No new safety signals were reported, and treatment with danuglipron was not associated with increased incidence of liver enzyme elevation compared to placebo. Future development of danuglipron will be focused on a once-daily formulation, with pharmacokinetic data anticipated in the first half of 2024, which will help to inform a potential path forward.
▪Marstacimab
•In December 2023, Pfizer announced the FDA had accepted the company’s Biologics License Application (BLA) for its anti-tissue factor pathway inhibitor (anti-TFPI) candidate marstacimab for individuals living with hemophilia A or hemophilia B without inhibitors to Factor VIII (FVIII) or Factor IX (FIX). A marketing authorization application for marstacimab is also currently under review by the EMA. The FDA has set a PDUFA action date in the fourth quarter of 2024, and a decision from the EC is anticipated by the first quarter of 2025.
- 9 -
•In December 2023, Pfizer presented results from the pivotal Phase 3 BASIS clinical trial evaluating marstacimab for the treatment of people with severe hemophilia A and moderately severe to severe hemophilia B without inhibitors to FVIII or FIX. Results from the BASIS trial, which were presented at the 2023 American Society of Hematology Annual Meeting and Exposition, demonstrated a statistically significant and clinically meaningful effect on annualized bleeding rate. The safety profile for marstacimab was consistent with Phase 1/2 results, and treatment was generally well-tolerated in the study. No deaths were reported, and there have been no thromboembolic events or events of consumptive coagulopathy recorded in hemophilia patients in clinical trials investigating marstacimab.
▪Vepdegestrant (ARV-471) – In December 2023, Arvinas, Inc. and Pfizer presented interim results from the Phase 1b trial evaluating vepdegestrant, a novel oral PROteolysis TArgeting Chimera (PROTAC) estrogen receptor (ER) degrader, in combination with palbociclib (Ibrance). Study data from the combination cohort demonstrated encouraging clinical activity in heavily pre-treated patients with a median of four lines of therapy across disease settings with locally advanced or metastatic ER positive/human epidermal growth factor 2 (HER2) negative (ER+/HER2-) breast cancer. These data were presented in a spotlight presentation at the 2023 San Antonio Breast Cancer Symposium.
▪VLA15 (Lyme Disease Vaccine Candidate) – In December 2023, Pfizer and Valneva SE announced the completion of recruitment for the Phase 3 VALOR trial evaluating VLA15, an investigational multivalent protein subunit vaccine for Lyme disease. The trial builds on previous positive Phase 1 and 2 trial results and includes both adult and pediatric participants, with the aim to confirm the efficacy, safety, lot consistency and immunogenicity of VLA15. The VALOR trial is expected to be concluded by the end of 2025.
Corporate Developments
▪In December 2023, Pfizer announced the completion of its acquisition of Seagen for $229 per share, in cash. The total fair value of the consideration transferred was $44 billion ($43 billion, net of cash acquired). To address U.S. Federal Trade Commission concerns, Pfizer has chosen to irrevocably donate the rights of royalties from sales of Bavencio(9) (avelumab) in the U.S. to the American Association for Cancer Research. With the addition of Seagen’s four in-line medicines, Adcetris (brentuximab vedotin), Padcev (enfortumab vedotin), Tivdak (tisotumab vedotin) and Tukysa (tucatinib), Pfizer’s industry-leading Oncology portfolio now includes over 25 approved medicines and biosimilars across more than 40 indications, including nine medicines that are either blockbuster or have the potential to be blockbuster.
▪In December 2023, Pfizer announced changes in its commercial organization to incorporate Seagen and improve focus, speed and quality of execution, effective January 1, 2024. Three new organizations have been created, each led by a member of Pfizer’s executive leadership team reporting to Dr. Albert Bourla, Chairman and Chief Executive Officer: (1) the Pfizer Oncology Division, which brings together U.S.
- 10 -
oncology commercial operations from both Pfizer and Seagen and is led by Chris Boshoff, M.D., Ph.D., Chief Oncology Officer, Executive Vice President, who also leads Pfizer’s newly combined global oncology R&D operations; (2) the Pfizer U.S. Commercial Division, led by Aamir Malik, Chief U.S. Commercial Officer, Executive Vice President; and (3) the Pfizer International Commercial Division, led by Alexandre de Germay, who has joined Pfizer as Chief International Commercial Officer, Executive Vice President.
- 11 -
For additional details, see the attached financial schedules, product revenue tables and disclosure notice.
(1)As used in this document, “Comirnaty” refers to, as applicable, and as authorized or approved, the Pfizer-BioNTech COVID-19 Vaccine, the Pfizer-BioNTech COVID-19 Vaccine, Bivalent (Original and Omicron BA.4/BA.5), Comirnaty (COVID-19 Vaccine, mRNA, 2023-2024 Formula), the Pfizer-BioNTech COVID-19 Vaccine (2023-2024 Formula), Comirnaty Original/Omicron BA.1, Comirnaty Original/Omicron BA.4/BA.5 and Comirnaty XBB.1.5. “Comirnaty” includes direct sales and alliance revenues related to sales of the above-mentioned vaccines, which are recorded within Pfizer’s Primary Care customer group. It does not include revenues for certain Comirnaty-related manufacturing activities performed on behalf of BioNTech, which are included in the Pfizer CentreOne contract development and manufacturing organization. Revenues related to these manufacturing activities totaled $33 million for full-year 2023 and $188 million for full-year 2022.
(2)Revenues is defined as revenues in accordance with U.S. generally accepted accounting principles (GAAP). Reported net income/(loss) and its components are defined as net income/(loss) attributable to Pfizer Inc. common shareholders and its components in accordance with U.S. GAAP. Reported diluted earnings per share (EPS) and reported diluted loss per share (LPS) are defined as diluted EPS or LPS attributable to Pfizer Inc. common shareholders in accordance with U.S. GAAP.
(3)Adjusted income and Adjusted diluted EPS are defined as U.S. GAAP net income attributable to Pfizer Inc. common shareholders and Reported diluted EPS attributable to Pfizer Inc. common shareholders before the impact of amortization of intangible assets, certain acquisition-related items, discontinued operations and certain significant items. See the accompanying reconciliations of certain GAAP Reported to Non-GAAP Adjusted information for the fourth quarter and full-year 2023 and 2022. Adjusted income and its components and Adjusted diluted EPS measures are not, and should not be viewed as, substitutes for U.S. GAAP net income/(loss) and its components and diluted EPS/(LPS)(2). See the Non-GAAP Financial Measure: Adjusted Income section of Management’s Discussion and Analysis of Financial Condition and Results of Operations in Pfizer’s 2022 Annual Report on Form 10-K and the accompanying Non-GAAP Financial Measure: Adjusted Income section of this press release for a definition of each component of Adjusted income as well as other relevant information.
(4)Significant one-time impacts to Reported(2) and Adjusted(3) diluted EPS/LPS:
▪Full-year 2023 Reported(2) and Adjusted(3) diluted EPS were significantly impacted by $5.6 billion of non-cash COVID product inventory write-offs and related charges in third-quarter 2023 and by a $3.5 billion non-cash Paxlovid revenue reversal in fourth-quarter 2023, which together unfavorably impacted Reported(2) and Adjusted(3) diluted EPS by $(1.36).
- 12 -
▪Fourth-quarter 2023 Reported(2) and Adjusted(3) diluted LPS/EPS were significantly impacted by a $3.5 billion non-cash Paxlovid revenue reversal in fourth quarter 2023, which unfavorably impacted Reported(2) and Adjusted(3) diluted LPS/EPS by approximately $(0.54).
(5)Pfizer does not provide guidance for GAAP Reported financial measures (other than revenues) or a reconciliation of forward-looking non-GAAP financial measures to the most directly comparable GAAP Reported financial measures on a forward-looking basis because it is unable to predict with reasonable certainty the ultimate outcome of unusual gains and losses, certain acquisition-related expenses, gains and losses from equity securities, actuarial gains and losses from pension and postretirement plan remeasurements, potential future asset impairments and pending litigation without unreasonable effort. These items are uncertain, depend on various factors, and could have a material impact on GAAP Reported results for the guidance period.
Financial guidance for full-year 2024 reflects the following:
▪Does not assume the completion of any business development transactions not completed as of December 31, 2023.
▪An anticipated immaterial impact in fiscal-year 2024 of recent and expected generic and biosimilar competition for certain products that have recently lost patent protection or that are anticipated to lose patent protection.
▪Exchange rates assumed are actual rates at mid-November 2023. Financial guidance reflects the anticipated unfavorable impact of approximately $0.3 billion on revenues and approximately $0.01 on Adjusted(3) diluted EPS as a result of changes in foreign exchange rates relative to the U.S. dollar compared to foreign exchange rates from 2023.
▪Guidance for Adjusted(3) diluted EPS assumes diluted weighted-average shares outstanding of approximately 5.75 billion shares, and assumes no share repurchases in 2024.
(6)Pfizer’s fiscal year-end for international subsidiaries is November 30 while Pfizer’s fiscal year-end for U.S. subsidiaries is December 31. Therefore, Pfizer’s fourth quarter and full year for U.S. subsidiaries reflects the three and twelve months ended on December 31, 2023 and December 31, 2022, while Pfizer’s fourth quarter and full year for subsidiaries operating outside the U.S. reflects the three and twelve months ended on November 30, 2023 and November 30, 2022.
(7)References to operational variances in this press release pertain to period-over-period changes that exclude the impact of foreign exchange rates. Although exchange rate changes are part of Pfizer’s business, they are not within Pfizer’s control, and because they can mask positive or negative trends in the business,
- 13 -
Pfizer believes presenting operational variances excluding these foreign exchange changes provides useful information to evaluate Pfizer’s results.
(8)Keytruda is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.
(9)Bavencio is a registered trademark of Merck KGaA.
| Contacts: | Media | Investors | ||||||||||||
| PfizerMediaRelations@Pfizer.com | 212.733.1226 | IR@Pfizer.com | 212.733.4848 | |||||||||||
- 14 -
PFIZER INC. AND SUBSIDIARY COMPANIES
CONSOLIDATED STATEMENTS OF OPERATIONS(1)
(UNAUDITED)
(millions, except per share data)
| Fourth-Quarter | % Incr. / | Full-Year | % Incr. / | |||||||||||||||||||||||||||||||||||
| 2023 | 2022 | (Decr.) | 2023 | 2022 | (Decr.) | |||||||||||||||||||||||||||||||||
Revenues: | ||||||||||||||||||||||||||||||||||||||
Product revenues(2) | $ | 12,339 | $ | 22,073 | (44) | $ | 50,914 | $ | 91,793 | (45) | ||||||||||||||||||||||||||||
Alliance revenues | 1,910 | 2,217 | (14) | 7,582 | 8,537 | (11) | ||||||||||||||||||||||||||||||||
Total revenues | 14,249 | 24,290 | (41) | 58,496 | 100,330 | (42) | ||||||||||||||||||||||||||||||||
| Costs and expenses: | ||||||||||||||||||||||||||||||||||||||
Cost of sales(3), (4) | 7,562 | 9,648 | (22) | 24,954 | 34,344 | (27) | ||||||||||||||||||||||||||||||||
Selling, informational and administrative expenses(4) | 4,575 | 4,644 | (1) | 14,771 | 13,677 | 8 | ||||||||||||||||||||||||||||||||
Research and development expenses(4) | 2,815 | 3,615 | (22) | 10,679 | 11,428 | (7) | ||||||||||||||||||||||||||||||||
Acquired in-process research and development expenses(5) | 73 | 73 | — | 194 | 953 | (80) | ||||||||||||||||||||||||||||||||
| Amortization of intangible assets | 1,267 | 1,130 | 12 | 4,733 | 3,609 | 31 | ||||||||||||||||||||||||||||||||
Restructuring charges and certain acquisition-related costs(6) | 2,566 | 795 | * | 2,943 | 1,375 | * | ||||||||||||||||||||||||||||||||
Other (income)/deductions––net(7) | (480) | (846) | (43) | (835) | 217 | * | ||||||||||||||||||||||||||||||||
Income/(loss) from continuing operations before provision/(benefit) for taxes on income/(loss) | (4,129) | 5,231 | * | 1,058 | 34,729 | (97) | ||||||||||||||||||||||||||||||||
Provision/(benefit) for taxes on income/(loss)(8) | (795) | 230 | * | (1,115) | 3,328 | * | ||||||||||||||||||||||||||||||||
Income/(loss) from continuing operations | (3,335) | 5,000 | * | 2,172 | 31,401 | (93) | ||||||||||||||||||||||||||||||||
Discontinued operations––net of tax(1) | (26) | 2 | * | (15) | 6 | * | ||||||||||||||||||||||||||||||||
Net income/(loss) before allocation to noncontrolling interests | (3,361) | 5,002 | * | 2,158 | 31,407 | (93) | ||||||||||||||||||||||||||||||||
| Less: Net income attributable to noncontrolling interests | 8 | 8 | 10 | 39 | 35 | 12 | ||||||||||||||||||||||||||||||||
Net income/(loss) attributable to Pfizer Inc. common shareholders | $ | (3,369) | $ | 4,995 | * | $ | 2,119 | $ | 31,372 | (93) | ||||||||||||||||||||||||||||
Earnings/(loss) per common share––basic: | ||||||||||||||||||||||||||||||||||||||
Income/(loss) from continuing operations attributable to Pfizer Inc. common shareholders | $ | (0.59) | $ | 0.89 | * | $ | 0.38 | $ | 5.59 | (93) | ||||||||||||||||||||||||||||
| Discontinued operations––net of tax | — | — | — | — | — | — | ||||||||||||||||||||||||||||||||
Net income/(loss) attributable to Pfizer Inc. common shareholders | $ | (0.60) | $ | 0.89 | * | $ | 0.38 | $ | 5.59 | (93) | ||||||||||||||||||||||||||||
Earnings/(loss) per common share––diluted: | ||||||||||||||||||||||||||||||||||||||
Income/(loss) from continuing operations attributable to Pfizer Inc. common shareholders | $ | (0.59) | $ | 0.87 | * | $ | 0.37 | $ | 5.47 | (93) | ||||||||||||||||||||||||||||
| Discontinued operations––net of tax | — | — | * | — | — | — | ||||||||||||||||||||||||||||||||
Net income/(loss) attributable to Pfizer Inc. common shareholders | $ | (0.60) | $ | 0.87 | * | $ | 0.37 | $ | 5.47 | (93) | ||||||||||||||||||||||||||||
Weighted-average shares used to calculate earnings/(loss) per common share: | ||||||||||||||||||||||||||||||||||||||
Basic | 5,647 | 5,615 | 5,643 | 5,608 | ||||||||||||||||||||||||||||||||||
Diluted(9) | 5,647 | 5,743 | 5,709 | 5,733 | ||||||||||||||||||||||||||||||||||
*Indicates calculation not meaningful.
- 15 -
PFIZER INC. AND SUBSIDIARY COMPANIES
NOTES TO CONSOLIDATED STATEMENTS OF OPERATIONS - (UNAUDITED)
(1)The financial statements present the three and twelve months ended December 31, 2023 and December 31, 2022. Subsidiaries operating outside the U.S. are included for the three and twelve months ended November 30, 2023 and November 30, 2022.
Business development activities impacted financial results in the periods presented. On December 14, 2023, we acquired Seagen Inc. (Seagen), a global biotechnology company that discovers, develops and commercializes transformative cancer medicines, for $229 per share in cash. The total fair value of the consideration transferred was $44 billion ($43 billion, net of cash acquired). As part of the financing for our acquisition of Seagen, we issued $31 billion of long-term debt in May 2023 and $8 billion of commercial paper in the fourth quarter of 2023. See Notes 1A and 2 to the condensed consolidated financial statements and the Overview of Our Performance, Operating Environment, Strategy and Outlook––Our Business Development Initiatives section of Management’s Discussion and Analysis of Financial Condition and Results of Operations in Pfizer’s Quarterly Report on Form 10-Q for the quarterly period ended October 1, 2023, as well as Notes 1A and 2 to the consolidated financial statements in our 2022 Form 10-K. Discontinued operations––net of tax in the periods presented relate to post-close adjustments.
In the fourth quarter of 2023, we began reporting Product revenues and Alliance revenues as separate line items in our consolidated statements of operations. Prior-period amounts have been reclassified to conform to the current presentation.
Certain amounts in the consolidated statements of operations and associated notes may not add due to rounding. All percentages have been calculated using unrounded amounts.
(2)2023 amounts reflect a non-cash Paxlovid revenue reversal of $3.5 billion recorded in the fourth quarter of 2023, of which a portion was associated with sales recorded in 2022, related to the expected return of an estimated 6.5 million treatment courses of EUA-labeled U.S. government inventory.
(3)For full-year 2023, Cost of sales includes non-cash charges of $6.2 billion for inventory write-offs and related charges ($5.0 billion for Paxlovid and $1.2 billion for Comirnaty).
(4)Exclusive of amortization of intangible assets.
(5)Acquired in-process research and development expenses includes costs incurred in connection with (a) all upfront and milestone payments on collaboration and in-license agreements, including premiums on equity securities and (b) asset acquisitions of acquired in-process research and development.
(6)Restructuring charges and certain acquisition-related costs include the following:
| Fourth-Quarter | Full-Year | |||||||||||||||||||||||||
| (MILLIONS) | 2023 | 2022 | 2023 | 2022 | ||||||||||||||||||||||
Restructuring charges/(credits)––acquisition-related costs(a) | $ | 190 | $ | 64 | $ | 231 | $ | 138 | ||||||||||||||||||
Restructuring charges/(credits)––cost reduction initiatives(b) | 1,613 | 450 | 1,738 | 744 | ||||||||||||||||||||||
Restructuring charges/(credits) | 1,803 | 514 | 1,968 | 882 | ||||||||||||||||||||||
Transaction costs(c) | 176 | 102 | 190 | 144 | ||||||||||||||||||||||
Integration costs and other(d) | 587 | 178 | 785 | 348 | ||||||||||||||||||||||
Restructuring charges and certain acquisition-related costs | $ | 2,566 | $ | 795 | $ | 2,943 | $ | 1,375 | ||||||||||||||||||
(a)Includes charges/(credits) for employee terminations, asset impairments and other exit costs associated with business combinations.
(b)Includes charges/(credits) for employee terminations, asset impairments and other exit costs not associated with acquisitions. The fourth quarter and full-year 2023 include charges of $1.5 billion for employee termination costs associated with our enterprise-wide cost realignment program.
(c)Transaction costs represent external costs for banking, legal, accounting and other similar services.
(d)Integration costs and other represent external, incremental costs directly related to integrating acquired businesses, such as expenditures for consulting and the integration of systems and processes, and certain other qualifying costs.
- 16 -
PFIZER INC. AND SUBSIDIARY COMPANIES
NOTES TO CONSOLIDATED STATEMENTS OF OPERATIONS - (UNAUDITED)
(7)Components of Other (income)/deductions––net include:
| Fourth-Quarter | Full-Year | |||||||||||||||||||||||||
| (MILLIONS) | 2023 | 2022 | 2023 | 2022 | ||||||||||||||||||||||
| Interest income | $ | (609) | $ | (137) | $ | (1,624) | $ | (251) | ||||||||||||||||||
| Interest expense | 689 | 313 | 2,209 | 1,238 | ||||||||||||||||||||||
Net interest expense(a) | 80 | 176 | 585 | 987 | ||||||||||||||||||||||
| Royalty-related income | (321) | (217) | (1,058) | (845) | ||||||||||||||||||||||
Net (gains)/losses recognized during the period on equity securities(b) | (2,299) | (79) | (1,590) | 1,273 | ||||||||||||||||||||||
| Income from collaborations, out-licensing arrangements and sales of compound/product rights | (70) | (170) | (154) | (188) | ||||||||||||||||||||||
| Net periodic benefit costs/(credits) other than service costs | (350) | (555) | (610) | (849) | ||||||||||||||||||||||
Certain legal matters, net(c) | 229 | 55 | 474 | 230 | ||||||||||||||||||||||
Certain asset impairments(d) | 2,760 | 221 | 3,024 | 421 | ||||||||||||||||||||||
| Haleon/Consumer Healthcare JV equity method (income)/loss | (151) | (154) | (505) | (436) | ||||||||||||||||||||||
Other, net(e) | (357) | (124) | (1,002) | (378) | ||||||||||||||||||||||
| Other (income)/deductions––net | $ | (480) | $ | (846) | $ | (835) | $ | 217 | ||||||||||||||||||
(a)The decrease in net interest expense in the fourth quarter and for full-year 2023 reflects higher interest expense driven by our $31 billion aggregate principal amount of senior unsecured notes issued in May 2023 as part of the financing for our acquisition of Seagen, which was more than offset by higher interest income on the investment of the net proceeds from the debt issuance.
(b)The net gains in the fourth quarter and full-year 2023 primarily include, among other things, a realized gain of $1.7 billion related to our investment in Telavant Holdings, Inc.
(c)The fourth quarter of 2023 primarily includes certain product liability and other legal expenses related to products discontinued and/or divested by Pfizer. Full-year 2023 also includes legal obligations related to pre-acquisition matters. The fourth quarter and full-year 2022 primarily included certain product liability and other legal expenses related to products discontinued and/or divested by Pfizer.
(d)The amount for the fourth quarter of 2023 represents, and for full-year 2023 includes, intangible asset impairment charges of $2.8 billion, composed of: (i) $1.4 billion for etrasimod (Velsipity), an in-process research and development (IPR&D) asset acquired in our Arena Pharmaceuticals Inc. acquisition, based on a change in development plans for additional indications and overall revenue expectations, (ii) $964 million for Prevnar 13 ($834 million for pediatric and $130 million for adult) developed technology rights acquired in our Wyeth acquisition, due to updated commercial forecasts mainly reflecting a transition to vaccines with higher serotype coverage, as well as (iii) other IPR&D and developed technology impairments totaling $366 million, due to updated commercial forecasts mainly reflecting competitive pressures. Full-year 2023 also includes intangible asset impairment charges of $128 million related to IPR&D and developed technology rights for acquired software assets, and $120 million resulting from the discontinuation of a study related to an out-licensed IPR&D asset for the treatment of prostate cancer. The amount for the fourth quarter of 2022 represented, and for full-year 2022 included, intangible asset impairment charges of $221 million, primarily related to developed technology rights acquired in connection with our Hospira, Inc. acquisition. The amount for full-year 2022 also included an IPR&D intangible asset impairment charge of $200 million resulting from the discontinuation of the PF-07265803 (lamin A/C protein (LMNA)-related dilated cardiomyopathy) clinical program.
(e)Full-year 2023 includes, among other things, (i) dividend income of $265 million from our investment in ViiV Healthcare Limited and $211 million from our investment in Nimbus Therapeutics, LLC (Nimbus) resulting from Takeda Pharmaceutical Company Limited’s acquisition of Nimbus’s oral, selective allosteric tyrosine kinase 2 (TYK2) inhibitor program subsidiary, and (ii) a $222 million gain on the divestiture of our early-stage rare disease gene therapy portfolio to Alexion Pharma International Operations Limited, a subsidiary of AstraZeneca PLC.
- 17 -
PFIZER INC. AND SUBSIDIARY COMPANIES
NOTES TO CONSOLIDATED STATEMENTS OF OPERATIONS - (UNAUDITED)
(8)Our effective tax rates for income/(loss) from continuing operations were 19.2% and (105.4)% in the three and twelve months ended December 31, 2023, respectively, and 4.4% and 9.6% in the three and twelve months ended December 31, 2022, respectively. The positive effective tax rate for the fourth quarter of 2023 reflects the tax benefit on a pre-tax loss and includes changes in the jurisdictional mix of earnings and the resolution of uncertain tax positions in various markets. The tax benefits of $795 million and $1.1 billion for the fourth quarter and full-year 2023, respectively, compared to the tax provisions of $230 million and $3.3 billion for the fourth quarter and full-year 2022, respectively, were primarily a result of changes in the jurisdictional mix of earnings and the resolution of uncertain tax positions in various markets. The tax provisions for the fourth quarter and full-year 2022 included tax benefits related to global income tax resolutions in multiple tax jurisdictions spanning multiple tax years. Full-year 2022 also included the closing of U.S. Internal Revenue Service audits covering five tax years.
(9)For the fourth quarter of 2023, basic weighted-average shares outstanding of 5,647 million (excluding common share equivalents) were used to calculate GAAP Reported Loss per common share attributable to Pfizer Inc. common shareholders––diluted.
- 18 -
PFIZER INC. AND SUBSIDIARY COMPANIES
NON-GAAP FINANCIAL MEASURE: ADJUSTED INCOME
Adjusted income is an alternative measure of performance used by management to evaluate our overall performance as a supplement to our GAAP Reported performance measures. As such, we believe that investors’ understanding of our performance is enhanced by disclosing this measure. We use Adjusted income, certain components of Adjusted income and Adjusted diluted EPS to present the results of our major operations––the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide––prior to considering certain income statement elements as follows:
| Measure | Definition | Relevance of Metrics to Our Business Performance | ||||||||||||
Adjusted income | Net income attributable to Pfizer Inc. common shareholders(a) before the impact of amortization of intangible assets, certain acquisition-related items, discontinued operations and certain significant items | •Provides investors useful information to: ◦evaluate the normal recurring operational activities, and their components, on a comparable year-over-year basis ◦assist in modeling expected future performance on a normalized basis •Provides investors insight into the way we manage our budgeting and forecasting, how we evaluate and manage our recurring operations and how we reward and compensate our senior management(b) | ||||||||||||
Adjusted cost of sales, Adjusted selling, informational and administrative expenses, Adjusted research and development expenses and Adjusted other (income)/deductions––net | Cost of sales, Selling, informational and administrative expenses, Research and development expenses and Other (income)/deductions––net (a), each before the impact of amortization of intangible assets, certain acquisition-related items, discontinued operations and certain significant items, which are components of the Adjusted income measure | |||||||||||||
Adjusted diluted EPS | EPS attributable to Pfizer Inc. common shareholders––diluted (a) before the impact of amortization of intangible assets, certain acquisition-related items, discontinued operations and certain significant items | |||||||||||||
(a)Most directly comparable GAAP measure.
(b)Beginning in the first quarter of 2022, we no longer exclude any expenses for acquired IPR&D from our non-GAAP Adjusted results but we continue to exclude certain of these expenses for our financial results for annual incentive compensation purposes.
Adjusted income and its components and Adjusted diluted EPS are non-GAAP financial measures that have no standardized meaning prescribed by GAAP and, therefore, are limited in their usefulness to investors. Because of their non-standardized definitions, they may not be comparable to the calculation of similar measures of other companies and are presented to permit investors to more fully understand how management assesses performance. A limitation of these measures is that they provide a view of our operations without including all events during a period, and do not provide a comparable view of our performance to peers. These measures are not, and should not be viewed as, substitutes for their most directly comparable GAAP measures of Net income/(loss) attributable to Pfizer Inc. common shareholders, components of Net income/(loss) attributable to Pfizer Inc. common shareholders and EPS/(LPS) attributable to Pfizer Inc. common shareholders—diluted, respectively.
We also recognize that, as internal measures of performance, these measures have limitations, and we do not restrict our performance-management process solely to these measures. We also use other tools designed to achieve the highest levels of performance. For example, our R&D organization has productivity targets, upon which its effectiveness is measured. In addition, total shareholder return, both on an absolute basis and relative to a publicly traded pharmaceutical index, plays a significant role in determining payouts under certain of our incentive compensation plans.
See the reconciliations of certain GAAP Reported to Non-GAAP Adjusted information for the fourth quarters and full-year 2023 and 2022 below and the Non-GAAP Financial Measure: Adjusted Income section of Management’s Discussion and Analysis of Financial Condition and Results of Operations in Pfizer’s 2022 Annual Report on Form 10-K for additional information.
- 19 -
PFIZER INC. AND SUBSIDIARY COMPANIES
RECONCILIATIONS OF GAAP REPORTED TO NON-GAAP ADJUSTED INFORMATION
CERTAIN LINE ITEMS - (UNAUDITED)
(millions, except per share data)
| Fourth-Quarter 2023 | |||||||||||||||||||||||||||||||||||
| Data presented will not (in all cases) aggregate to totals. | Cost of sales(1) | Selling, informational and administrative expenses(1) | Other (income)/deductions––net(1) | Net income/(loss) attributable to Pfizer Inc. common shareholders(1), (2) | Earnings/(loss) per common share attributable to Pfizer Inc. common shareholders––diluted(3) | ||||||||||||||||||||||||||||||
| GAAP Reported | $ | 7,562 | $ | 4,575 | $ | (480) | $ | (3,369) | $ | (0.60) | |||||||||||||||||||||||||
| Amortization of intangible assets | — | — | — | 1,267 | |||||||||||||||||||||||||||||||
| Acquisition-related items | (269) | (4) | 130 | 1,097 | |||||||||||||||||||||||||||||||
Discontinued operations(4) | — | — | — | — | |||||||||||||||||||||||||||||||
| Certain significant items: | |||||||||||||||||||||||||||||||||||
Restructuring charges/(credits) and implementation costs and additional depreciation—asset restructuring(5) | (28) | (94) | — | 1,777 | |||||||||||||||||||||||||||||||
Certain asset impairments(6) | — | — | (2,760) | 2,760 | |||||||||||||||||||||||||||||||
| (Gains)/losses on equity securities | — | — | 2,298 | (2,298) | |||||||||||||||||||||||||||||||
| Actuarial valuation and other pension and postretirement plan (gains)/losses | — | — | 264 | (264) | |||||||||||||||||||||||||||||||
Other(7) | — | (6) | (268) | 276 | |||||||||||||||||||||||||||||||
| Income tax provision—non-GAAP items | (653) | ||||||||||||||||||||||||||||||||||
| Non-GAAP Adjusted | $ | 7,265 | $ | 4,471 | $ | (815) | (8) | $ | 593 | $ | 0.10 | ||||||||||||||||||||||||
| Full-Year Ended December 31, 2023 | |||||||||||||||||||||||||||||||||||
| Data presented will not (in all cases) aggregate to totals. | Cost of sales(1) | Selling, informational and administrative expenses(1) | Other (income)/deductions––net(1) | Net income/(loss) attributable to Pfizer Inc. common shareholders(1), (2) | Earnings/(loss) per common share attributable to Pfizer Inc. common shareholders––diluted | ||||||||||||||||||||||||||||||
| GAAP Reported | $ | 24,954 | $ | 14,771 | $ | (835) | $ | 2,119 | $ | 0.37 | |||||||||||||||||||||||||
| Amortization of intangible assets | — | — | — | 4,733 | |||||||||||||||||||||||||||||||
| Acquisition-related items | (629) | (11) | (28) | 1,874 | |||||||||||||||||||||||||||||||
Discontinued operations(4) | — | — | — | (11) | |||||||||||||||||||||||||||||||
| Certain significant items: | |||||||||||||||||||||||||||||||||||
Restructuring charges/(credits) and implementation costs and additional depreciation—asset restructuring(5) | (98) | (290) | — | 2,227 | |||||||||||||||||||||||||||||||
Certain asset impairments(6) | — | — | (3,024) | 3,024 | |||||||||||||||||||||||||||||||
| (Gains)/losses on equity securities | — | — | 1,588 | (1,588) | |||||||||||||||||||||||||||||||
| Actuarial valuation and other pension and postretirement plan (gains)/losses | — | — | 265 | (265) | |||||||||||||||||||||||||||||||
Other(7) | (238) | (24) | (246) | 518 | |||||||||||||||||||||||||||||||
| Income tax provision—Non-GAAP items | (2,131) | ||||||||||||||||||||||||||||||||||
| Non-GAAP Adjusted | $ | 23,988 | $ | 14,446 | $ | (2,281) | (8) | $ | 10,501 | $ | 1.84 | ||||||||||||||||||||||||
See end of tables for notes.
- 20 -
PFIZER INC. AND SUBSIDIARY COMPANIES
RECONCILIATIONS OF GAAP REPORTED TO NON-GAAP ADJUSTED INFORMATION
CERTAIN LINE ITEMS - (UNAUDITED)
(millions, except per share data)
| Fourth-Quarter 2022 | |||||||||||||||||||||||||||||||||||
| Data presented will not (in all cases) aggregate to totals. | Cost of sales(1) | Selling, informational and administrative expenses(1) | Other (income)/deductions––net(1) | Net income/(loss) attributable to Pfizer Inc. common shareholders(1), (2) | Earnings/(loss) per common share attributable to Pfizer Inc. common shareholders––diluted | ||||||||||||||||||||||||||||||
| GAAP Reported | $ | 9,648 | $ | 4,644 | $ | (846) | $ | 4,995 | $ | 0.87 | |||||||||||||||||||||||||
| Amortization of intangible assets | — | — | — | 1,130 | |||||||||||||||||||||||||||||||
| Acquisition-related items | (131) | (2) | (23) | 501 | |||||||||||||||||||||||||||||||
Discontinued operations(4) | — | — | — | (12) | |||||||||||||||||||||||||||||||
| Certain significant items: | |||||||||||||||||||||||||||||||||||
Restructuring charges/(credits) and implementation costs and additional depreciation—asset restructuring(5) | (26) | (217) | — | 695 | |||||||||||||||||||||||||||||||
Certain asset impairments(6) | — | — | (221) | 221 | |||||||||||||||||||||||||||||||
| (Gains)/losses on equity securities | — | — | 78 | (78) | |||||||||||||||||||||||||||||||
| Actuarial valuation and other pension and postretirement plan (gains)/losses | — | — | 455 | (455) | |||||||||||||||||||||||||||||||
Other(7) | (16) | (11) | (100) | 130 | |||||||||||||||||||||||||||||||
| Income tax provision—non-GAAP items | (576) | ||||||||||||||||||||||||||||||||||
| Non-GAAP Adjusted | $ | 9,475 | $ | 4,414 | $ | (656) | (8) | $ | 6,551 | $ | 1.14 | ||||||||||||||||||||||||
| Full-Year Ended December 31, 2022 | |||||||||||||||||||||||||||||||||||
| Data presented will not (in all cases) aggregate to totals. | Cost of sales(1) | Selling, informational and administrative expenses(1) | Other (income)/deductions––net(1) | Net income/(loss) attributable to Pfizer Inc. common shareholders(1), (2) | Earnings/(loss) per common share attributable to Pfizer Inc. common shareholders––diluted | ||||||||||||||||||||||||||||||
| GAAP Reported | $ | 34,344 | $ | 13,677 | $ | 217 | $ | 31,372 | $ | 5.47 | |||||||||||||||||||||||||
| Amortization of intangible assets | — | — | — | 3,609 | |||||||||||||||||||||||||||||||
| Acquisition-related items | (119) | (7) | (74) | 832 | |||||||||||||||||||||||||||||||
Discontinued operations(4) | — | — | — | (21) | |||||||||||||||||||||||||||||||
| Certain significant items: | |||||||||||||||||||||||||||||||||||
Restructuring charges/(credits) and implementation costs and additional depreciation—asset restructuring(5) | (88) | (562) | — | 1,396 | |||||||||||||||||||||||||||||||
Certain asset impairments(6) | — | — | (421) | 421 | |||||||||||||||||||||||||||||||
| (Gains)/losses on equity securities | — | — | (1,270) | 1,270 | |||||||||||||||||||||||||||||||
| Actuarial valuation and other pension and postretirement plan (gains)/losses | — | — | 230 | (230) | |||||||||||||||||||||||||||||||
Other(7) | (40) | (59) | (636) | 752 | |||||||||||||||||||||||||||||||
| Income tax provision—Non-GAAP items | (1,683) | ||||||||||||||||||||||||||||||||||
| Non-GAAP Adjusted | $ | 34,096 | $ | 13,049 | $ | (1,954) | (8) | $ | 37,717 | $ | 6.58 | ||||||||||||||||||||||||
- 21 -
PFIZER INC. AND SUBSIDIARY COMPANIES
NOTES TO RECONCILIATIONS OF GAAP REPORTED TO NON-GAAP ADJUSTED INFORMATION
CERTAIN LINE ITEMS - (UNAUDITED)
(1)Items that reconcile GAAP Reported to non-GAAP Adjusted balances are shown pre-tax. Our effective tax rates for GAAP Reported income/(loss) from continuing operations were 19.2% and (105.4)% in the three and twelve months ended December 31, 2023, respectively, and 4.4% and 9.6% in the three and twelve months ended December 31, 2022, respectively. See Note (8) to the Consolidated Statements of Operations above. Our effective tax rates for non-GAAP Adjusted income/(loss) were (24.0)% and 9.0% in the three and twelve months ended December 31, 2023, respectively, and 11.1% and 11.7% in the three and twelve months ended December 31, 2022, respectively.
(2)The amounts for the fourth quarters and full-year 2023 and 2022 include reconciling amounts for Research and development expenses that are not material to our non-GAAP consolidated results of operations.
(3)For the fourth quarter of 2023, basic weighted-average shares outstanding of 5,647 million (excluding common share equivalents) were used to calculate GAAP Reported Loss per common share attributable to Pfizer Inc. common shareholders––diluted.
(4)The amounts for the fourth quarters and full-year 2023 and 2022 relate to post-close adjustments.
(5)Includes employee termination costs, asset impairments and other exit costs related to our cost-reduction and productivity initiatives not associated with acquisitions.
(6)See Note (7) to the Consolidated Statements of Operations above.
(7)For the fourth quarter of 2023, the total Other (income)/deductions––net adjustment of $268 million includes charges of $229 million for certain legal matters, primarily representing certain product liability and other legal expenses related to products discontinued and/or divested by Pfizer. For full-year 2023, the total Cost of sales adjustment of $238 million mainly includes $286 million in inventory losses, overhead costs related to the period in which the facility could not operate, and incremental costs resulting from tornado damage to our manufacturing facility in Rocky Mount, NC in July 2023, partially offset by insurance recoveries received in the fourth quarter of 2023. For full-year 2023, the total Other (income)/deductions––net adjustment of $246 million includes charges of (i) $474 million for certain legal matters, primarily representing certain product liability and other legal expenses related to products discontinued and/or divested by Pfizer, and to a lesser extent, legal obligations related to pre-acquisition matters, and (ii) $127 million mostly related to our equity-method accounting pro-rata share of intangible asset amortization and impairments, costs of separating from GSK plc (GSK) and restructuring costs recorded by Haleon plc (Haleon), partially offset by: (i) a $222 million gain on the divestiture of our early-stage rare disease gene therapy portfolio to Alexion Pharma International Operations Limited, a subsidiary of AstraZeneca plc and (ii) dividend income of $211 million related to our investment in Nimbus Therapeutics, LLC (Nimbus) resulting from Takeda Pharmaceutical Company Limited’s acquisition of Nimbus’s oral, selective allosteric tyrosine kinase 2 (TYK2) inhibitor program subsidiary. For 2022, the total Other (income)/deductions––net adjustments of $100 million for the fourth quarter and $636 million for the full year primarily included (i) charges of $34 million and $307 million, respectively, mostly representing our equity-method accounting pro rata share of restructuring charges and costs of separating from GSK recorded by Haleon/the GSK Consumer Healthcare JV, and adjustments to our equity-method basis differences which are also related to the separation of Haleon/the GSK Consumer Healthcare JV from GSK, and (ii) charges for certain legal matters of $55 million and $230 million, respectively, primarily representing certain product liability and other legal expenses related to products discontinued and/or divested by Pfizer.
(8)The components of non-GAAP Adjusted Other (income)/deductions––net include the following:
| Fourth-Quarter | Full-Year | |||||||||||||||||||||||||
(MILLIONS) | 2023 | 2022 | 2023 | 2022 | ||||||||||||||||||||||
| Interest income | $ | (609) | $ | (137) | $ | (1,624) | $ | (251) | ||||||||||||||||||
| Interest expense | 691 | 315 | 2,218 | 1,247 | ||||||||||||||||||||||
Net interest expense | 82 | 178 | 595 | 995 | ||||||||||||||||||||||
| Royalty-related income | (321) | (217) | (1,058) | (845) | ||||||||||||||||||||||
Net (gains)/losses recognized during the period on equity securities | (1) | (1) | (2) | 4 | ||||||||||||||||||||||
Income from collaborations, out-licensing arrangements and sales of compound/product rights | (70) | (170) | (154) | (188) | ||||||||||||||||||||||
| Net periodic benefit costs/(credits) other than service costs | (86) | (99) | (346) | (619) | ||||||||||||||||||||||
| Haleon/Consumer Healthcare JV equity method (income)/loss | (186) | (188) | (632) | (743) | ||||||||||||||||||||||
| Other, net | (233) | (159) | (684) | (559) | ||||||||||||||||||||||
Non-GAAP Adjusted Other (income)/deductions––net | $ | (815) | $ | (656) | $ | (2,281) | $ | (1,954) | ||||||||||||||||||
See Note (7) to the Consolidated Statements of Operations above for additional information on the components comprising GAAP Reported Other (income)/deductions––net.
- 22 -
PFIZER INC. - REVENUES
FOURTH-QUARTER 2023 and 2022 - (UNAUDITED)
| WORLDWIDE | UNITED STATES | TOTAL INTERNATIONAL(a) | ||||||||||||||||||||||||||||||||||||
| 2023 | 2022 | % Change | 2023 | 2022 | % Change | 2023 | 2022 | % Change | ||||||||||||||||||||||||||||||
| (MILLIONS) | Total | Oper. | Total | Total | Oper. | |||||||||||||||||||||||||||||||||
| TOTAL REVENUES | $ | 14,249 | $ | 24,290 | (41%) | (42%) | $ | 4,591 | $ | 8,481 | (46%) | $ | 9,657 | $ | 15,808 | (39%) | (39%) | |||||||||||||||||||||
GLOBAL BIOPHARMACEUTICALS BUSINESS (BIOPHARMA)(b) | $ | 13,867 | $ | 23,922 | (42%) | (42%) | $ | 4,490 | $ | 8,382 | (46%) | $ | 9,376 | $ | 15,539 | (40%) | (40%) | |||||||||||||||||||||
| Primary Care | $ | 6,986 | $ | 17,348 | (60%) | (60%) | $ | 787 | $ | 4,815 | (84%) | $ | 6,200 | $ | 12,533 | (51%) | (51%) | |||||||||||||||||||||
Comirnaty direct sales and alliance revenues(c) | 5,361 | 11,329 | (53%) | (54%) | 1,064 | 2,472 | (57%) | 4,297 | 8,857 | (51%) | (53%) | |||||||||||||||||||||||||||
| Eliquis alliance revenues and direct sales | 1,612 | 1,479 | 9% | 9% | 931 | 843 | 10% | 681 | 636 | 7% | 7% | |||||||||||||||||||||||||||
Prevnar family(d) | 1,605 | 1,736 | (8%) | (7%) | 994 | 1,022 | (3%) | 612 | 714 | (14%) | (14%) | |||||||||||||||||||||||||||
Paxlovid(e) | (3,135) | 1,834 | * | * | (3,249) | — | * | 114 | 1,834 | (94%) | (95%) | |||||||||||||||||||||||||||
| Nurtec ODT/Vydura | 282 | 211 | 33% | 33% | 275 | 211 | 31% | 7 | 1 | * | * | |||||||||||||||||||||||||||
Abrysvo | 515 | — | * | * | 513 | — | * | 2 | — | * | * | |||||||||||||||||||||||||||
| Premarin family | 98 | 128 | (23%) | (23%) | 88 | 119 | (26%) | 10 | 9 | 13% | 13% | |||||||||||||||||||||||||||
| BMP2 | 86 | 76 | 12% | 12% | 86 | 76 | 12% | — | — | — | — | |||||||||||||||||||||||||||
| FSME-IMMUN/TicoVac | 30 | 23 | 33% | 24% | — | 1 | (57%) | 30 | 22 | 36% | 27% | |||||||||||||||||||||||||||
Nimenrix | 58 | 48 | 22% | 26% | — | — | — | 58 | 48 | 22% | 26% | |||||||||||||||||||||||||||
Trumenba | 17 | 15 | 19% | 16% | 12 | 12 | 4% | 5 | 3 | 79% | 68% | |||||||||||||||||||||||||||
| All other Primary Care | 457 | 469 | (3%) | — | 73 | 60 | 23% | 384 | 409 | (6%) | (3%) | |||||||||||||||||||||||||||
| Specialty Care | $ | 3,949 | $ | 3,566 | 11% | 11% | $ | 1,771 | $ | 1,553 | 14% | $ | 2,178 | $ | 2,013 | 8% | 9% | |||||||||||||||||||||
Vyndaqel family(f) | 961 | 680 | 41% | 39% | 534 | 355 | 51% | 427 | 326 | 31% | 27% | |||||||||||||||||||||||||||
Xeljanz | 493 | 493 | — | — | 360 | 327 | 10% | 133 | 165 | (19%) | (19%) | |||||||||||||||||||||||||||
Enbrel (Outside the U.S. and Canada) | 203 | 236 | (14%) | (12%) | — | — | — | 203 | 236 | (14%) | (12%) | |||||||||||||||||||||||||||
| Sulperazon | 138 | 189 | (27%) | (25%) | — | — | — | 138 | 189 | (27%) | (25%) | |||||||||||||||||||||||||||
Ig Portfolio(g) | 156 | 135 | 15% | 15% | 156 | 135 | 15% | — | — | — | — | |||||||||||||||||||||||||||
| Genotropin | 160 | 99 | 61% | 65% | 47 | 27 | 75% | 112 | 72 | 55% | 61% | |||||||||||||||||||||||||||
| Zavicefta | 133 | 109 | 22% | 31% | — | — | — | 133 | 109 | 22% | 31% | |||||||||||||||||||||||||||
| Inflectra | 117 | 129 | (10%) | (11%) | 63 | 62 | 1% | 54 | 68 | (19%) | (22%) | |||||||||||||||||||||||||||
| BeneFIX | 103 | 101 | 2% | 5% | 54 | 54 | (1%) | 49 | 46 | 6% | 11% | |||||||||||||||||||||||||||
| Zithromax | 152 | 81 | 89% | 91% | — | 1 | (70%) | 152 | 80 | 90% | 93% | |||||||||||||||||||||||||||
| Medrol | 76 | 93 | (18%) | (19%) | 21 | 43 | (51%) | 55 | 50 | 9% | 8% | |||||||||||||||||||||||||||
| Oxbryta | 96 | 73 | 32% | 32% | 94 | 72 | 30% | 2 | — | * | * | |||||||||||||||||||||||||||
| Somavert | 67 | 66 | 1% | — | 27 | 27 | (1%) | 40 | 39 | 2% | — | |||||||||||||||||||||||||||
| Fragmin | 63 | 67 | (5%) | (8%) | — | 1 | (82%) | 63 | 65 | (3%) | (7%) | |||||||||||||||||||||||||||
| Refacto AF/Xyntha | 52 | 52 | 1% | 5% | 14 | 11 | 24% | 38 | 40 | (6%) | (1%) | |||||||||||||||||||||||||||
| Cresemba | 54 | 41 | 34% | 30% | — | — | — | 54 | 41 | 34% | 30% | |||||||||||||||||||||||||||
| Vfend | 34 | 55 | (38%) | (37%) | 1 | 1 | (36%) | 33 | 54 | (38%) | (37%) | |||||||||||||||||||||||||||
| Bicillin | 24 | 38 | (36%) | (36%) | 21 | 35 | (39%) | 2 | 2 | (3%) | (1%) | |||||||||||||||||||||||||||
| Cibinqo | 37 | 10 | * | * | 20 | 6 | * | 18 | 5 | * | * | |||||||||||||||||||||||||||
| All other Anti-infectives | 272 | 270 | 1% | 3% | 62 | 74 | (16%) | 210 | 197 | 7% | 11% | |||||||||||||||||||||||||||
| All other Specialty Care | 558 | 551 | 1% | 2% | 298 | 321 | (7%) | 260 | 230 | 13% | 16% | |||||||||||||||||||||||||||
| Oncology | $ | 2,932 | $ | 3,007 | (3%) | (2%) | $ | 1,932 | $ | 2,014 | (4%) | $ | 999 | $ | 993 | 1% | 1% | |||||||||||||||||||||
| Ibrance | 1,118 | 1,279 | (13%) | (13%) | 712 | 876 | (19%) | 405 | 403 | 1% | (1%) | |||||||||||||||||||||||||||
Xtandi alliance revenues | 314 | 320 | (2%) | (2%) | 314 | 320 | (2%) | — | — | — | — | |||||||||||||||||||||||||||
Inlyta | 263 | 243 | 8% | 9% | 166 | 164 | 1% | 97 | 79 | 24% | 27% | |||||||||||||||||||||||||||
| Bosulif | 182 | 150 | 21% | 21% | 120 | 98 | 22% | 62 | 52 | 19% | 19% | |||||||||||||||||||||||||||
| Lorbrena | 146 | 95 | 53% | 55% | 60 | 48 | 25% | 86 | 47 | 82% | 86% | |||||||||||||||||||||||||||
| Zirabev | 88 | 130 | (32%) | (32%) | 66 | 97 | (31%) | 22 | 33 | (34%) | (32%) | |||||||||||||||||||||||||||
| Ruxience | 88 | 101 | (13%) | (12%) | 62 | 83 | (25%) | 26 | 18 | 43% | 46% | |||||||||||||||||||||||||||
Xalkori | 91 | 103 | (12%) | (10%) | 25 | 27 | (7%) | 66 | 76 | (13%) | (11%) | |||||||||||||||||||||||||||
| Retacrit | 79 | 86 | (8%) | (10%) | 58 | 65 | (11%) | 21 | 21 | 1% | (5%) | |||||||||||||||||||||||||||
| Aromasin | 76 | 61 | 24% | 26% | — | 1 | (15%) | 75 | 61 | 24% | 27% | |||||||||||||||||||||||||||
| Besponsa | 65 | 55 | 18% | 18% | 36 | 31 | 18% | 28 | 24 | 17% | 17% | |||||||||||||||||||||||||||
Braftovi | 57 | 37 | 53% | 57% | 55 | 36 | 50% | 2 | 1 | * | * | |||||||||||||||||||||||||||
Bavencio alliance revenues(h) | 4 | 72 | (95%) | (94%) | 2 | 27 | (91%) | 2 | 46 | (96%) | (96%) | |||||||||||||||||||||||||||
| Sutent | 44 | 60 | (27%) | (26%) | 4 | 4 | 12% | 39 | 56 | (30%) | (29%) | |||||||||||||||||||||||||||
Mektovi | 46 | 46 | — | — | 46 | 46 | 1% | — | — | — | — | |||||||||||||||||||||||||||
| Trazimera | 23 | 54 | (56%) | (53%) | (8) | 21 | * | 32 | 33 | (5%) | 1% | |||||||||||||||||||||||||||
Padcev(i) | 52 | — | * | * | 52 | — | * | — | — | — | — | |||||||||||||||||||||||||||
Adcetris(i) | 46 | — | * | * | 46 | — | * | — | — | — | — | |||||||||||||||||||||||||||
Tukysa(i) | 17 | — | * | * | 17 | — | * | — | — | — | — | |||||||||||||||||||||||||||
Tivdak(i) | 4 | — | * | * | 4 | — | * | — | — | — | — | |||||||||||||||||||||||||||
All other Oncology | 129 | 113 | 14% | 14% | 93 | 70 | 32% | 36 | 43 | (17%) | (15%) | |||||||||||||||||||||||||||
BUSINESS INNOVATION(b) | $ | 382 | $ | 368 | 4% | 2% | $ | 101 | $ | 99 | 2% | $ | 281 | $ | 269 | 4% | 2% | |||||||||||||||||||||
Pfizer CentreOne(j) | 363 | 363 | — | (2%) | 82 | 94 | (13%) | 281 | 269 | 4% | 2% | |||||||||||||||||||||||||||
| Pfizer Ignite | 20 | 5 | * | * | 20 | 5 | * | — | — | — | — | |||||||||||||||||||||||||||
| Total Alliance revenues included above | $ | 1,910 | $ | 2,217 | (14%) | (15%) | $ | 1,290 | $ | 1,216 | 6% | $ | 620 | $ | 1,001 | (38%) | (40%) | |||||||||||||||||||||
See end of tables for notes.
- 23 -
PFIZER INC.
INTERNATIONAL REVENUES BY GEOGRAPHIC REGION
FOURTH-QUARTER 2023 and 2022 - (UNAUDITED)
DEVELOPED EUROPE(k) | DEVELOPED REST OF WORLD(l) | EMERGING MARKETS(m) | |||||||||||||||||||||||||||||||||||||||
| 2023 | 2022 | % Change | 2023 | 2022 | % Change | 2023 | 2022 | % Change | |||||||||||||||||||||||||||||||||
| (MILLIONS) | Total | Oper. | Total | Oper. | Total | Oper. | |||||||||||||||||||||||||||||||||||
| TOTAL INTERNATIONAL REVENUES | $ | 4,433 | $ | 7,277 | (39%) | (43%) | $ | 2,909 | $ | 5,107 | (43%) | (42%) | $ | 2,315 | $ | 3,424 | (32%) | (28%) | |||||||||||||||||||||||
GLOBAL BIOPHARMACEUTICALS BUSINESS (BIOPHARMA)(b) | $ | 4,242 | $ | 7,064 | (40%) | (44%) | $ | 2,889 | $ | 5,084 | (43%) | (42%) | $ | 2,245 | $ | 3,390 | (34%) | (30%) | |||||||||||||||||||||||
| Primary Care | $ | 3,043 | $ | 6,008 | (49%) | (52%) | $ | 2,343 | $ | 4,486 | (48%) | (47%) | $ | 814 | $ | 2,040 | (60%) | (58%) | |||||||||||||||||||||||
Comirnaty direct sales and alliance revenues(c) | 2,107 | 4,285 | (51%) | (54%) | 1,954 | 3,642 | (46%) | (45%) | 236 | 930 | (75%) | (76%) | |||||||||||||||||||||||||||||
| Eliquis alliance revenues and direct sales | 385 | 359 | 7% | 1% | 69 | 82 | (16%) | (14%) | 227 | 194 | 17% | 28% | |||||||||||||||||||||||||||||
Prevnar family(d) | 175 | 174 | 1% | (5%) | 88 | 86 | 3% | 4% | 348 | 455 | (23%) | (20%) | |||||||||||||||||||||||||||||
| Paxlovid | 174 | 995 | (82%) | (84%) | 166 | 599 | (72%) | (73%) | (227) | 241 | * | * | |||||||||||||||||||||||||||||
| Nurtec ODT/Vydura | 1 | — | * | * | — | — | — | — | 6 | 1 | * | * | |||||||||||||||||||||||||||||
Abrysvo | 2 | — | * | * | — | — | — | — | — | — | — | — | |||||||||||||||||||||||||||||
| Premarin family | 1 | — | * | * | 5 | 5 | 2% | 4% | 4 | 3 | 19% | 19% | |||||||||||||||||||||||||||||
| BMP2 | — | — | — | — | — | — | — | — | — | — | — | — | |||||||||||||||||||||||||||||
| FSME-IMMUN/TicoVac | 26 | 20 | 30% | 22% | — | — | — | — | 4 | 2 | 99% | 85% | |||||||||||||||||||||||||||||
| Nimenrix | 19 | 24 | (18%) | (23%) | 4 | 5 | (17%) | (15%) | 34 | 19 | 84% | * | |||||||||||||||||||||||||||||
Trumenba | 4 | 2 | 97% | 84% | — | — | — | — | 1 | 1 | 26% | 17% | |||||||||||||||||||||||||||||
| All other Primary Care | 148 | 149 | — | (6%) | 56 | 66 | (15%) | (13%) | 180 | 195 | (8%) | 3% | |||||||||||||||||||||||||||||
| Specialty Care | $ | 795 | $ | 670 | 19% | 11% | $ | 377 | $ | 390 | (3%) | (2%) | $ | 1,006 | $ | 954 | 6% | 12% | |||||||||||||||||||||||
Vyndaqel family(f) | 328 | 239 | 37% | 29% | 69 | 62 | 10% | 13% | 30 | 24 | 25% | 44% | |||||||||||||||||||||||||||||
| Xeljanz | 53 | 62 | (15%) | (21%) | 31 | 51 | (38%) | (36%) | 49 | 52 | (5%) | — | |||||||||||||||||||||||||||||
| Enbrel (Outside the U.S. and Canada) | 84 | 87 | (4%) | (10%) | 38 | 42 | (9%) | (7%) | 81 | 107 | (24%) | (16%) | |||||||||||||||||||||||||||||
| Sulperazon | — | — | — | — | — | 1 | (99%) | (99%) | 138 | 188 | (27%) | (25%) | |||||||||||||||||||||||||||||
Ig Portfolio(g) | — | — | — | — | — | — | — | — | — | — | — | — | |||||||||||||||||||||||||||||
| Genotropin | 37 | 25 | 47% | 38% | 18 | 20 | (7%) | (7%) | 57 | 27 | * | * | |||||||||||||||||||||||||||||
| Zavicefta | 31 | 27 | 14% | 7% | 1 | — | * | * | 101 | 82 | 23% | 37% | |||||||||||||||||||||||||||||
| Inflectra | 25 | 31 | (18%) | (24%) | 27 | 34 | (21%) | (20%) | 2 | 3 | (13%) | (19%) | |||||||||||||||||||||||||||||
| BeneFIX | 10 | 11 | (16%) | (22%) | 12 | 12 | (5%) | (7%) | 28 | 23 | 22% | 37% | |||||||||||||||||||||||||||||
| Zithromax | 15 | 15 | (5%) | (11%) | 6 | 4 | 50% | 53% | 131 | 60 | * | * | |||||||||||||||||||||||||||||
| Medrol | 16 | 14 | 13% | 6% | 11 | 10 | 11% | 14% | 29 | 27 | 7% | 7% | |||||||||||||||||||||||||||||
| Oxbryta | 1 | — | * | * | — | — | — | — | 1 | — | * | * | |||||||||||||||||||||||||||||
| Somavert | 30 | 29 | 3% | (3%) | 5 | 5 | 4% | 6% | 5 | 5 | (4%) | 16% | |||||||||||||||||||||||||||||
| Fragmin | 40 | 35 | 12% | 6% | 13 | 14 | (2%) | — | 10 | 16 | (38%) | (40%) | |||||||||||||||||||||||||||||
| Refacto AF/Xyntha | 15 | 15 | 5% | (2%) | 3 | 3 | (6%) | (8%) | 20 | 23 | (13%) | 1% | |||||||||||||||||||||||||||||
| Cresemba | 36 | 29 | 22% | 14% | 1 | — | 55% | 53% | 18 | 11 | 67% | 72% | |||||||||||||||||||||||||||||
| Vfend | 3 | 3 | (7%) | (13%) | 7 | 10 | (25%) | (24%) | 23 | 41 | (43%) | (41%) | |||||||||||||||||||||||||||||
| Bicillin | — | — | — | — | 2 | 2 | (4%) | (2%) | — | — | — | — | |||||||||||||||||||||||||||||
| Cibinqo | 5 | 2 | * | * | 4 | 1 | * | * | 9 | 2 | * | * | |||||||||||||||||||||||||||||
| All other Anti-infectives | 37 | 33 | 12% | 5% | 19 | 21 | (7%) | (5%) | 154 | 143 | 8% | 14% | |||||||||||||||||||||||||||||
| All other Specialty Care | 31 | 12 | * | * | 109 | 98 | 11% | 13% | 121 | 120 | 1% | 6% | |||||||||||||||||||||||||||||
| Oncology | $ | 405 | $ | 387 | 5% | (2%) | $ | 169 | $ | 209 | (19%) | (17%) | $ | 425 | $ | 397 | 7% | 14% | |||||||||||||||||||||||
| Ibrance | 220 | 188 | 17% | 10% | 78 | 98 | (20%) | (19%) | 107 | 118 | (9%) | (4%) | |||||||||||||||||||||||||||||
| Xtandi alliance revenues | — | — | — | — | — | — | — | — | — | — | — | — | |||||||||||||||||||||||||||||
| Inlyta | 35 | 21 | 68% | 58% | 16 | 16 | — | 2% | 46 | 42 | 11% | 22% | |||||||||||||||||||||||||||||
| Bosulif | 26 | 23 | 12% | 5% | 16 | 16 | (2%) | 2% | 20 | 13 | 57% | 64% | |||||||||||||||||||||||||||||
| Lorbrena | 23 | 17 | 31% | 23% | 8 | 11 | (20%) | (17%) | 55 | 19 | * | * | |||||||||||||||||||||||||||||
| Zirabev | 15 | 22 | (33%) | (37%) | 2 | 9 | (77%) | (75%) | 5 | 2 | * | * | |||||||||||||||||||||||||||||
| Ruxience | 6 | 6 | 7% | — | 13 | 6 | * | * | 7 | 6 | 17% | 30% | |||||||||||||||||||||||||||||
| Xalkori | 17 | 19 | (14%) | (20%) | 8 | 9 | (9%) | (8%) | 41 | 47 | (14%) | (8%) | |||||||||||||||||||||||||||||
| Retacrit | 21 | 20 | 6% | (1%) | — | — | — | — | — | 1 | (85%) | (86%) | |||||||||||||||||||||||||||||
| Aromasin | 5 | 5 | (8%) | (14%) | 1 | 1 | 2% | 3% | 69 | 54 | 28% | 32% | |||||||||||||||||||||||||||||
| Besponsa | 14 | 9 | 58% | 48% | 8 | 6 | 29% | 31% | 7 | 10 | (27%) | (20%) | |||||||||||||||||||||||||||||
| Braftovi | — | — | — | — | 2 | 1 | 96% | 99% | 1 | — | * | * | |||||||||||||||||||||||||||||
Bavencio alliance revenues(h) | 2 | 22 | (93%) | (93%) | — | 15 | * | * | — | 9 | (96%) | (92%) | |||||||||||||||||||||||||||||
| Sutent | 2 | 9 | (78%) | (79%) | 9 | 12 | (27%) | (25%) | 28 | 35 | (19%) | (17%) | |||||||||||||||||||||||||||||
| Mektovi | — | — | — | — | — | — | — | — | — | — | — | — | |||||||||||||||||||||||||||||
| Trazimera | 7 | 9 | (24%) | (29%) | 3 | 2 | 45% | 48% | 21 | 22 | (1%) | 9% | |||||||||||||||||||||||||||||
Padcev | — | — | — | — | — | — | — | — | — | — | — | — | |||||||||||||||||||||||||||||
Adcetris | — | — | — | — | — | — | — | — | — | — | — | — | |||||||||||||||||||||||||||||
Tukysa | — | — | — | — | — | — | — | — | — | — | — | — | |||||||||||||||||||||||||||||
Tivdak | — | — | — | — | — | — | — | — | — | — | — | — | |||||||||||||||||||||||||||||
All other Oncology | 14 | 17 | (18%) | (23%) | 5 | 6 | (12%) | (11%) | 17 | 20 | (17%) | (10%) | |||||||||||||||||||||||||||||
BUSINESS INNOVATION(b) | $ | 191 | $ | 213 | (10%) | (14%) | $ | 21 | $ | 23 | (9%) | (5%) | $ | 70 | $ | 34 | * | * | |||||||||||||||||||||||
Pfizer CentreOne(j) | 191 | 213 | (10%) | (14%) | 21 | 23 | (9%) | (5%) | 70 | 34 | * | * | |||||||||||||||||||||||||||||
| Pfizer Ignite | — | — | — | — | — | — | — | — | — | — | — | — | |||||||||||||||||||||||||||||
| Total Alliance revenues included above | $ | 551 | $ | 887 | (38%) | (40%) | $ | 69 | $ | 101 | (32%) | (30%) | $ | — | $ | 13 | (97%) | (88%) | |||||||||||||||||||||||
- 24 -
PFIZER INC. - REVENUES
TWELVE MONTHS 2023 and 2022 - (UNAUDITED)
| WORLDWIDE | UNITED STATES | TOTAL INTERNATIONAL(a) | ||||||||||||||||||||||||||||||||||||
| 2023 | 2022 | % Change | 2023 | 2022 | % Change | 2023 | 2022 | % Change | ||||||||||||||||||||||||||||||
| (MILLIONS) | Total | Oper. | Total | Total | Oper. | |||||||||||||||||||||||||||||||||
| TOTAL REVENUES | $ | 58,496 | $ | 100,330 | (42%) | (41%) | $ | 27,088 | $ | 42,473 | (36%) | $ | 31,408 | $ | 57,857 | (46%) | (44%) | |||||||||||||||||||||
GLOBAL BIOPHARMACEUTICALS BUSINESS (BIOPHARMA)(b) | $ | 57,186 | $ | 98,988 | (42%) | (41%) | $ | 26,698 | $ | 42,083 | (37%) | $ | 30,488 | $ | 56,905 | (46%) | (45%) | |||||||||||||||||||||
| Primary Care | $ | 30,589 | $ | 73,023 | (58%) | (57%) | $ | 12,470 | $ | 28,503 | (56%) | $ | 18,119 | $ | 44,521 | (59%) | (58%) | |||||||||||||||||||||
Comirnaty direct sales and alliance revenues(c) | 11,220 | 37,806 | (70%) | (70%) | 2,404 | 8,775 | (73%) | 8,816 | 29,032 | (70%) | (69%) | |||||||||||||||||||||||||||
| Eliquis alliance revenues and direct sales | 6,747 | 6,480 | 4% | 5% | 4,228 | 3,822 | 11% | 2,519 | 2,658 | (5%) | (3%) | |||||||||||||||||||||||||||
Prevnar family(d) | 6,440 | 6,337 | 2% | 3% | 4,204 | 4,032 | 4% | 2,236 | 2,305 | (3%) | — | |||||||||||||||||||||||||||
Paxlovid(e) | 1,279 | 18,933 | (93%) | (92%) | (1,289) | 10,514 | * | 2,568 | 8,419 | (69%) | (68%) | |||||||||||||||||||||||||||
| Nurtec ODT/Vydura | 928 | 213 | * | * | 908 | 211 | * | 20 | 2 | * | * | |||||||||||||||||||||||||||
Abrysvo | 890 | — | * | * | 888 | — | * | 2 | — | * | * | |||||||||||||||||||||||||||
| Premarin family | 397 | 455 | (13%) | (13%) | 361 | 420 | (14%) | 36 | 36 | 2% | 6% | |||||||||||||||||||||||||||
| BMP2 | 338 | 277 | 22% | 22% | 338 | 277 | 22% | — | — | — | — | |||||||||||||||||||||||||||
| FSME-IMMUN/TicoVac | 268 | 200 | 34% | 32% | 3 | 2 | 26% | 265 | 198 | 34% | 32% | |||||||||||||||||||||||||||
Nimenrix | 179 | 268 | (33%) | (30%) | — | — | — | 179 | 268 | (33%) | (30%) | |||||||||||||||||||||||||||
Trumenba | 126 | 123 | 2% | 2% | 111 | 111 | — | 15 | 12 | 26% | 22% | |||||||||||||||||||||||||||
| All other Primary Care | 1,777 | 1,932 | (8%) | (4%) | 315 | 340 | (7%) | 1,462 | 1,592 | (8%) | (3%) | |||||||||||||||||||||||||||
| Specialty Care | $ | 14,970 | $ | 13,833 | 8% | 11% | $ | 6,601 | $ | 5,659 | 17% | $ | 8,370 | $ | 8,174 | 2% | 7% | |||||||||||||||||||||
Vyndaqel family(f) | 3,321 | 2,447 | 36% | 36% | 1,863 | 1,245 | 50% | 1,458 | 1,202 | 21% | 22% | |||||||||||||||||||||||||||
Xeljanz | 1,703 | 1,796 | (5%) | (4%) | 1,154 | 1,129 | 2% | 549 | 668 | (18%) | (15%) | |||||||||||||||||||||||||||
Enbrel (Outside the U.S. and Canada) | 830 | 1,003 | (17%) | (14%) | — | — | — | 830 | 1,003 | (17%) | (14%) | |||||||||||||||||||||||||||
| Sulperazon | 757 | 786 | (4%) | 2% | — | — | — | 757 | 786 | (4%) | 2% | |||||||||||||||||||||||||||
Ig Portfolio(g) | 584 | 491 | 19% | 19% | 584 | 491 | 19% | — | — | — | — | |||||||||||||||||||||||||||
| Genotropin | 539 | 360 | 50% | 56% | 153 | 68 | * | 386 | 292 | 32% | 39% | |||||||||||||||||||||||||||
| Zavicefta | 511 | 412 | 24% | 34% | — | — | — | 511 | 412 | 24% | 34% | |||||||||||||||||||||||||||
| Inflectra | 490 | 532 | (8%) | (7%) | 257 | 289 | (11%) | 233 | 243 | (4%) | (3%) | |||||||||||||||||||||||||||
| BeneFIX | 424 | 425 | — | 3% | 225 | 235 | (4%) | 200 | 191 | 5% | 13% | |||||||||||||||||||||||||||
| Zithromax | 406 | 331 | 23% | 29% | 1 | 2 | (41%) | 404 | 328 | 23% | 29% | |||||||||||||||||||||||||||
| Medrol | 339 | 328 | 3% | 4% | 132 | 132 | — | 206 | 196 | 5% | 7% | |||||||||||||||||||||||||||
| Oxbryta | 328 | 73 | * | * | 323 | 72 | * | 5 | — | * | * | |||||||||||||||||||||||||||
| Somavert | 267 | 268 | — | 1% | 109 | 111 | (2%) | 158 | 157 | 1% | 2% | |||||||||||||||||||||||||||
| Fragmin | 238 | 269 | (11%) | (10%) | 2 | 4 | (45%) | 236 | 264 | (11%) | (10%) | |||||||||||||||||||||||||||
| Refacto AF/Xyntha | 230 | 239 | (4%) | — | 59 | 59 | — | 171 | 180 | (5%) | 1% | |||||||||||||||||||||||||||
| Cresemba | 195 | 155 | 26% | 27% | — | — | — | 195 | 155 | 26% | 27% | |||||||||||||||||||||||||||
| Vfend | 187 | 225 | (17%) | (12%) | 6 | 5 | 20% | 181 | 221 | (18%) | (13%) | |||||||||||||||||||||||||||
| Bicillin | 158 | 146 | 8% | 8% | 148 | 137 | 8% | 10 | 9 | 12% | 18% | |||||||||||||||||||||||||||
| Cibinqo | 128 | 27 | * | * | 46 | 11 | * | 81 | 16 | * | * | |||||||||||||||||||||||||||
| All other Anti-infectives | 1,092 | 1,171 | (7%) | (2%) | 258 | 317 | (19%) | 834 | 854 | (2%) | 3% | |||||||||||||||||||||||||||
| All other Specialty Care | 2,244 | 2,350 | (4%) | (2%) | 1,280 | 1,351 | (5%) | 965 | 999 | (3%) | 1% | |||||||||||||||||||||||||||
| Oncology | $ | 11,627 | $ | 12,132 | (4%) | (3%) | $ | 7,627 | $ | 7,921 | (4%) | $ | 4,000 | $ | 4,210 | (5%) | (1%) | |||||||||||||||||||||
| Ibrance | 4,753 | 5,120 | (7%) | (6%) | 3,151 | 3,370 | (6%) | 1,602 | 1,751 | (8%) | (6%) | |||||||||||||||||||||||||||
| Xtandi alliance revenues | 1,191 | 1,198 | (1%) | (1%) | 1,191 | 1,198 | (1%) | — | — | — | — | |||||||||||||||||||||||||||
| Inlyta | 1,036 | 1,003 | 3% | 5% | 642 | 618 | 4% | 394 | 385 | 3% | 7% | |||||||||||||||||||||||||||
| Bosulif | 645 | 575 | 12% | 13% | 444 | 375 | 19% | 200 | 200 | — | 3% | |||||||||||||||||||||||||||
| Lorbrena | 539 | 343 | 57% | 62% | 224 | 177 | 27% | 314 | 166 | 90% | 99% | |||||||||||||||||||||||||||
| Zirabev | 424 | 562 | (25%) | (24%) | 304 | 413 | (26%) | 119 | 149 | (20%) | (17%) | |||||||||||||||||||||||||||
| Ruxience | 390 | 458 | (15%) | (14%) | 308 | 403 | (23%) | 82 | 55 | 49% | 56% | |||||||||||||||||||||||||||
| Xalkori | 374 | 465 | (20%) | (16%) | 100 | 105 | (4%) | 274 | 361 | (24%) | (20%) | |||||||||||||||||||||||||||
| Retacrit | 340 | 394 | (14%) | (14%) | 259 | 312 | (17%) | 81 | 82 | (1%) | (2%) | |||||||||||||||||||||||||||
| Aromasin | 301 | 248 | 21% | 28% | 2 | 2 | (2%) | 298 | 246 | 21% | 28% | |||||||||||||||||||||||||||
| Besponsa | 236 | 219 | 8% | 10% | 134 | 126 | 7% | 102 | 93 | 9% | 13% | |||||||||||||||||||||||||||
| Braftovi | 213 | 194 | 10% | 11% | 203 | 191 | 6% | 10 | 3 | * | * | |||||||||||||||||||||||||||
Bavencio alliance revenues(h) | 190 | 271 | (30%) | (26%) | 62 | 101 | (39%) | 128 | 169 | (25%) | (19%) | |||||||||||||||||||||||||||
| Sutent | 180 | 347 | (48%) | (46%) | 20 | 33 | (39%) | 160 | 314 | (49%) | (47%) | |||||||||||||||||||||||||||
| Mektovi | 174 | 176 | (1%) | (1%) | 171 | 175 | (3%) | 3 | 1 | * | * | |||||||||||||||||||||||||||
| Trazimera | 91 | 203 | (55%) | (53%) | (8) | 106 | * | 99 | 97 | 2% | 8% | |||||||||||||||||||||||||||
Padcev(i) | 52 | — | * | * | 52 | — | * | — | — | — | — | |||||||||||||||||||||||||||
Adcetris(i) | 46 | — | * | * | 46 | — | * | — | — | — | — | |||||||||||||||||||||||||||
Tukysa(i) | 17 | — | * | * | 17 | — | * | — | — | — | — | |||||||||||||||||||||||||||
Tivdak(i) | 4 | — | * | * | 4 | — | * | — | — | — | — | |||||||||||||||||||||||||||
All other Oncology | 433 | 357 | 21% | 23% | 300 | 216 | 39% | 133 | 140 | (5%) | (1%) | |||||||||||||||||||||||||||
BUSINESS INNOVATION(b) | $ | 1,310 | $ | 1,342 | (2%) | (2%) | $ | 390 | $ | 390 | — | $ | 920 | $ | 952 | (3%) | (3%) | |||||||||||||||||||||
Pfizer CentreOne(j) | 1,265 | 1,335 | (5%) | (5%) | 345 | 383 | (10%) | 920 | 952 | (3%) | (3%) | |||||||||||||||||||||||||||
| Pfizer Ignite | 44 | 7 | * | * | 44 | 7 | * | — | — | — | — | |||||||||||||||||||||||||||
| Total Alliance revenues included above | $ | 7,582 | $ | 8,537 | (11%) | (11%) | $ | 5,628 | $ | 5,203 | 8% | $ | 1,955 | $ | 3,335 | (41%) | (41%) | |||||||||||||||||||||
- 25 -
PFIZER INC.
INTERNATIONAL REVENUES BY GEOGRAPHIC REGION
TWELVE MONTHS 2023 and 2022 - (UNAUDITED)
DEVELOPED EUROPE(k) | DEVELOPED REST OF WORLD(l) | EMERGING MARKETS(m) | |||||||||||||||||||||||||||||||||||||||
| 2023 | 2022 | % Change | 2023 | 2022 | % Change | 2023 | 2022 | % Change | |||||||||||||||||||||||||||||||||
| (MILLIONS) | Total | Oper. | Total | Oper. | Total | Oper. | |||||||||||||||||||||||||||||||||||
| TOTAL INTERNATIONAL REVENUES | $ | 11,650 | $ | 21,982 | (47%) | (48%) | $ | 7,761 | $ | 15,778 | (51%) | (48%) | $ | 11,996 | $ | 20,097 | (40%) | (37%) | |||||||||||||||||||||||
GLOBAL BIOPHARMACEUTICALS BUSINESS (BIOPHARMA)(b) | $ | 11,034 | $ | 21,260 | (48%) | (49%) | $ | 7,678 | $ | 15,692 | (51%) | (48%) | $ | 11,776 | $ | 19,954 | (41%) | (37%) | |||||||||||||||||||||||
| Primary Care | $ | 6,640 | $ | 16,882 | (61%) | (61%) | $ | 5,393 | $ | 13,137 | (59%) | (57%) | $ | 6,085 | $ | 14,502 | (58%) | (56%) | |||||||||||||||||||||||
Comirnaty direct sales and alliance revenues(c) | 3,335 | 10,827 | (69%) | (70%) | 3,707 | 8,330 | (55%) | (53%) | 1,774 | 9,875 | (82%) | (82%) | |||||||||||||||||||||||||||||
| Eliquis alliance revenues and direct sales | 1,389 | 1,459 | (5%) | (6%) | 282 | 407 | (31%) | (26%) | 848 | 793 | 7% | 14% | |||||||||||||||||||||||||||||
Prevnar family(d) | 529 | 512 | 3% | 2% | 321 | 337 | (5%) | 1% | 1,386 | 1,456 | (5%) | (1%) | |||||||||||||||||||||||||||||
| Paxlovid | 563 | 3,237 | (83%) | (82%) | 815 | 3,732 | (78%) | (77%) | 1,189 | 1,450 | (18%) | (11%) | |||||||||||||||||||||||||||||
| Nurtec ODT/Vydura | 2 | — | * | * | — | — | — | — | 17 | 2 | * | * | |||||||||||||||||||||||||||||
Abrysvo | 2 | — | * | * | — | — | — | — | — | — | — | — | |||||||||||||||||||||||||||||
| Premarin family | 1 | 1 | 8% | 7% | 18 | 19 | (6%) | (1%) | 17 | 15 | 11% | 14% | |||||||||||||||||||||||||||||
| BMP2 | — | — | — | — | — | — | — | — | — | — | — | — | |||||||||||||||||||||||||||||
| FSME-IMMUN/TicoVac | 218 | 160 | 36% | 35% | — | — | — | — | 47 | 37 | 25% | 21% | |||||||||||||||||||||||||||||
Nimenrix | 69 | 96 | (28%) | (29%) | 20 | 19 | 3% | 8% | 91 | 154 | (41%) | (36%) | |||||||||||||||||||||||||||||
Trumenba | 11 | 9 | 25% | 22% | — | — | — | — | 3 | 3 | 22% | 17% | |||||||||||||||||||||||||||||
| All other Primary Care | 521 | 582 | (11%) | (12%) | 230 | 293 | (21%) | (16%) | 712 | 718 | (1%) | 10% | |||||||||||||||||||||||||||||
| Specialty Care | $ | 2,850 | $ | 2,643 | 8% | 6% | $ | 1,525 | $ | 1,683 | (9%) | (4%) | $ | 3,994 | $ | 3,849 | 4% | 12% | |||||||||||||||||||||||
Vyndaqel family(f) | 1,097 | 821 | 34% | 31% | 251 | 308 | (18%) | (12%) | 110 | 73 | 50% | 65% | |||||||||||||||||||||||||||||
Xeljanz | 210 | 235 | (11%) | (12%) | 164 | 232 | (29%) | (24%) | 175 | 200 | (13%) | (6%) | |||||||||||||||||||||||||||||
Enbrel (Outside the U.S. and Canada) | 318 | 394 | (19%) | (20%) | 144 | 195 | (26%) | (21%) | 367 | 414 | (11%) | (3%) | |||||||||||||||||||||||||||||
Sulperazon | — | — | — | — | 1 | 4 | (86%) | (84%) | 756 | 782 | (3%) | 3% | |||||||||||||||||||||||||||||
Ig Portfolio(g) | — | — | — | — | — | — | — | — | — | — | — | — | |||||||||||||||||||||||||||||
Genotropin | 131 | 103 | 27% | 25% | 91 | 89 | 2% | 8% | 163 | 100 | 64% | 82% | |||||||||||||||||||||||||||||
| Zavicefta | 117 | 103 | 14% | 11% | 3 | 1 | * | * | 391 | 307 | 27% | 42% | |||||||||||||||||||||||||||||
| Inflectra | 102 | 120 | (15%) | (17%) | 120 | 112 | 8% | 13% | 11 | 11 | (2%) | (4%) | |||||||||||||||||||||||||||||
BeneFIX | 44 | 54 | (17%) | (18%) | 50 | 52 | (4%) | (1%) | 105 | 84 | 25% | 41% | |||||||||||||||||||||||||||||
Zithromax | 56 | 49 | 15% | 15% | 21 | 19 | 13% | 20% | 327 | 261 | 25% | 33% | |||||||||||||||||||||||||||||
Medrol | 61 | 56 | 9% | 7% | 39 | 36 | 8% | 14% | 106 | 103 | 3% | 5% | |||||||||||||||||||||||||||||
| Oxbryta | 4 | — | * | * | — | — | — | — | 1 | — | * | * | |||||||||||||||||||||||||||||
Somavert | 118 | 120 | (1%) | (3%) | 19 | 19 | — | 5% | 21 | 18 | 16% | 33% | |||||||||||||||||||||||||||||
Fragmin | 146 | 144 | 2% | 2% | 48 | 53 | (8%) | (4%) | 41 | 68 | (40%) | (39%) | |||||||||||||||||||||||||||||
Refacto AF/Xyntha | 63 | 77 | (19%) | (20%) | 14 | 16 | (12%) | (10%) | 94 | 87 | 8% | 20% | |||||||||||||||||||||||||||||
| Cresemba | 128 | 120 | 6% | 5% | 2 | 1 | 46% | 51% | 65 | 33 | 99% | * | |||||||||||||||||||||||||||||
Vfend | 11 | 13 | (15%) | (16%) | 32 | 39 | (19%) | (13%) | 138 | 168 | (18%) | (12%) | |||||||||||||||||||||||||||||
| Bicillin | — | — | — | — | 9 | 8 | 13% | 19% | 1 | 1 | — | 5% | |||||||||||||||||||||||||||||
| Cibinqo | 15 | 5 | * | * | 12 | 2 | * | * | 55 | 9 | * | * | |||||||||||||||||||||||||||||
All other Anti-infectives | 144 | 140 | 2% | 1% | 82 | 90 | (9%) | (4%) | 608 | 623 | (2%) | 5% | |||||||||||||||||||||||||||||
| All other Specialty Care | 83 | 87 | (4%) | (4%) | 423 | 407 | 4% | 9% | 459 | 506 | (9%) | (4%) | |||||||||||||||||||||||||||||
| Oncology | $ | 1,543 | $ | 1,735 | (11%) | (12%) | $ | 759 | $ | 872 | (13%) | (7%) | $ | 1,697 | $ | 1,603 | 6% | 13% | |||||||||||||||||||||||
| Ibrance | 764 | 845 | (10%) | (11%) | 338 | 408 | (17%) | (12%) | 500 | 498 | — | 7% | |||||||||||||||||||||||||||||
| Xtandi alliance revenues | — | — | — | — | — | — | — | — | — | — | — | — | |||||||||||||||||||||||||||||
| Inlyta | 145 | 153 | (5%) | (6%) | 63 | 72 | (12%) | (6%) | 186 | 160 | 16% | 24% | |||||||||||||||||||||||||||||
| Bosulif | 97 | 97 | (1%) | (2%) | 63 | 66 | (5%) | 2% | 41 | 36 | 14% | 21% | |||||||||||||||||||||||||||||
| Lorbrena | 80 | 66 | 21% | 19% | 43 | 39 | 10% | 18% | 192 | 61 | * | * | |||||||||||||||||||||||||||||
| Zirabev | 75 | 100 | (25%) | (26%) | 27 | 38 | (30%) | (25%) | 18 | 11 | 64% | 89% | |||||||||||||||||||||||||||||
| Ruxience | 26 | 21 | 23% | 22% | 33 | 25 | 35% | 41% | 23 | 9 | * | * | |||||||||||||||||||||||||||||
| Xalkori | 72 | 82 | (12%) | (13%) | 34 | 38 | (11%) | (6%) | 169 | 241 | (30%) | (24%) | |||||||||||||||||||||||||||||
| Retacrit | 80 | 79 | 1% | (1%) | — | — | — | — | 1 | 3 | (43%) | (44%) | |||||||||||||||||||||||||||||
| Aromasin | 23 | 24 | (5%) | (7%) | 5 | 6 | (15%) | (10%) | 271 | 216 | 25% | 33% | |||||||||||||||||||||||||||||
| Besponsa | 42 | 35 | 19% | 16% | 27 | 28 | (5%) | 1% | 33 | 30 | 11% | 23% | |||||||||||||||||||||||||||||
| Braftovi | — | — | — | — | 7 | 2 | * | * | 3 | — | * | * | |||||||||||||||||||||||||||||
Bavencio alliance revenues(h) | 58 | 79 | (27%) | (26%) | 45 | 64 | (31%) | (24%) | 25 | 26 | (1%) | 13% | |||||||||||||||||||||||||||||
| Sutent | 14 | 68 | (79%) | (79%) | 40 | 53 | (25%) | (20%) | 105 | 193 | (45%) | (43%) | |||||||||||||||||||||||||||||
| Mektovi | — | — | — | — | 3 | 1 | * | * | — | — | — | — | |||||||||||||||||||||||||||||
| Trazimera | 33 | 37 | (11%) | (11%) | 8 | 8 | 6% | 12% | 57 | 51 | 11% | 21% | |||||||||||||||||||||||||||||
Padcev | — | — | — | — | — | — | — | — | — | — | — | — | |||||||||||||||||||||||||||||
Adcetris | — | — | — | — | — | — | — | — | — | — | — | — | |||||||||||||||||||||||||||||
Tukysa | — | — | — | — | — | — | — | — | — | — | — | — | |||||||||||||||||||||||||||||
Tivdak | — | — | — | — | — | — | — | — | — | — | — | — | |||||||||||||||||||||||||||||
All other Oncology | 35 | 49 | (28%) | (29%) | 25 | 24 | 5% | 10% | 72 | 67 | 7% | 16% | |||||||||||||||||||||||||||||
BUSINESS INNOVATION(b) | $ | 616 | $ | 722 | (15%) | (15%) | $ | 83 | $ | 86 | (3%) | 4% | $ | 220 | $ | 143 | 54% | 52% | |||||||||||||||||||||||
Pfizer CentreOne(j) | 616 | 722 | (15%) | (15%) | 83 | 86 | (3%) | 4% | 220 | 143 | 54% | 52% | |||||||||||||||||||||||||||||
| Pfizer Ignite | — | — | — | — | — | — | — | — | — | — | — | — | |||||||||||||||||||||||||||||
| Total Alliance revenues included above | $ | 1,599 | $ | 2,749 | (42%) | (42%) | $ | 330 | $ | 489 | (32%) | (27%) | $ | 25 | $ | 97 | (74%) | (64%) | |||||||||||||||||||||||
- 26 -
PFIZER INC.
NOTES TO REVENUES TABLE INFORMATION
(UNAUDITED)
| (a) | Total International represents Developed Europe region + Developed Rest of World region + Emerging Markets region. Details for these regions are described in footnotes (k) to (m) below, respectively. | ||||
| (b) | In 2023, we managed our commercial operations through a global structure consisting of two operating segments, each led by a single manager: Biopharma, our innovative science-based biopharmaceutical business, and Business Innovation, an operating segment established in the first quarter of 2023 that includes Pfizer CentreOne (PC1), our global contract development and manufacturing organization and a leading supplier of specialty active pharmaceutical ingredients, and Pfizer Ignite, an offering that provides strategic guidance and end-to-end R&D services to select innovative biotech companies that align with our R&D focus areas. Prior-period financial information has been revised to reflect the current period presentation. | ||||
| (c) | Excludes revenues for certain Comirnaty-related manufacturing activities performed on behalf of BioNTech, which are included in the PC1 contract development and manufacturing organization. See footnote (j) below. | ||||
| (d) | Prevnar family includes revenues from Prevnar 20/Apexxnar (pediatric and adult) and Prevnar 13/Prevenar 13 (pediatric and adult). | ||||
| (e) | Includes a non-cash revenue reversal of $3.5 billion recorded in the fourth quarter of 2023, of which a portion was associated with sales recorded in 2022, related to the expected return of an estimated 6.5 million treatment courses of EUA-labeled U.S. government inventory. | ||||
| (f) | Vyndaqel family includes global revenues from Vyndaqel, as well as revenues for Vyndamax in the U.S. and Vynmac in Japan. | ||||
| (g) | Immunoglobulin (Ig) portfolio includes the revenues from Panzyga, Octagam and Cutaquig. | ||||
| (h) | In March 2023, it was announced that our alliance with Merck KGaA to co-develop and co-commercialize Bavencio (avelumab) would terminate. Effective June 30, 2023, Merck KGaA took full control of the global commercialization of Bavencio. Beginning in the third quarter of 2023, the related profit share was replaced by a 15% royalty to Pfizer on net sales of Bavencio, which was recorded in Other (income)/deductions––net. We and Merck KGaA continue to operationalize our respective ongoing clinical trials for Bavencio; and Merck KGaA controls all future R&D activities. Bavencio is a registered trademark of Merck KGaA. | ||||
| (i) | Represents revenues from legacy Seagen products subsequent to the acquisition on December 14, 2023. | ||||
| (j) | PC1 includes revenues from our contract manufacturing, including certain Comirnaty-related manufacturing activities performed on behalf of BioNTech ($33 million for full-year 2023 and $188 million for full-year 2022), and revenues from our active pharmaceutical ingredient sales operation, as well as revenues related to our manufacturing and supply agreements with former legacy Pfizer businesses/partnerships. | ||||
| (k) | Developed Europe region includes the following markets: Western Europe, Scandinavian countries and Finland. | ||||
(l) | Developed Rest of World region includes the following markets: Japan, Canada, South Korea, Australia and New Zealand. | ||||
(m) | Emerging Markets region includes, but is not limited to, the following markets: Asia (excluding Japan and South Korea), Latin America, Eastern Europe, Central Europe, the Middle East, Africa and Turkey. | ||||
| * | Indicates calculation not meaningful. | ||||
Amounts may not add due to rounding. All percentages have been calculated using unrounded amounts. | |||||
- 27 -
DISCLOSURE NOTICE: Except where otherwise noted, the information contained in this earnings release and the related attachments is as of January 30, 2024. We assume no obligation to update any forward-looking statements contained in this earnings release and the related attachments as a result of new information or future events or developments.
This earnings release and the related attachments contain forward-looking statements about, among other topics, our anticipated operating and financial performance, including financial guidance and projections; reorganizations; business plans, strategy, goals and prospects; our Environmental, Social and Governance (ESG) priorities, strategy and goals; expectations for our product pipeline, in-line products and product candidates, including anticipated regulatory submissions, data read-outs, study starts, approvals, launches, clinical trial results and other developing data, revenue contribution and projections, potential pricing and reimbursement, potential market dynamics, including patient demand, market size and utilization rates and growth, performance, timing of exclusivity and potential benefits; strategic reviews; capital allocation objectives; an enterprise-wide cost realignment program, which we launched in October 2023 (including anticipated costs, savings and potential benefits); dividends and share repurchases; plans for and prospects of our acquisitions, dispositions and other business development activities, including our recent acquisition of Seagen, and our ability to successfully capitalize on growth opportunities and prospects; manufacturing and product supply; our ongoing efforts to respond to COVID-19, including our plans and expectations regarding Comirnaty (as defined in this earnings release) and our oral COVID-19 treatment (Paxlovid); and our expectations regarding the impact of COVID-19 on our business, operations and financial results. Given their forward-looking nature, these statements involve substantial risks, uncertainties and potentially inaccurate assumptions and we cannot assure that any outcome expressed in these forward-looking statements will be realized in whole or in part. You can identify these statements by the fact that they use future dates or use words such as “will,” “may,” “could,” “likely,” “ongoing,” “anticipate,” “estimate,” “expect,” “project,” “intend,” “plan,” “believe,” “assume,” “target,” “forecast,” “guidance,” “goal,” “objective,” “aim,” “seek,” “potential,” “hope” and other words and terms of similar meaning. Pfizer’s financial guidance is based on estimates and assumptions that are subject to significant uncertainties.
Among the factors that could cause actual results to differ materially from past results and future plans and projected future results are the following:
Risks Related to Our Business, Industry and Operations, and Business Development:
•the outcome of research and development (R&D) activities, including, the ability to meet anticipated pre-clinical or clinical endpoints, commencement and/or completion dates for our pre-clinical or clinical trials, regulatory submission dates, and/or regulatory approval and/or launch dates; the possibility of unfavorable pre-clinical and clinical trial results, including the possibility of unfavorable new pre-clinical or clinical data and further analyses of existing pre-clinical or clinical data; risks associated with preliminary, early stage or interim data; the risk that pre-clinical and clinical trial data are subject to differing interpretations and assessments, including during the peer review/publication process, in the scientific community generally, and by regulatory authorities; and whether and when additional data from our pipeline programs will be published in scientific journal publications and, if so, when and with what modifications and interpretations;
•our ability to successfully address comments received from regulatory authorities such as the FDA or the EMA, or obtain approval for new products and indications from regulators on a timely basis or at all; regulatory decisions impacting labeling, including the scope of indicated patient populations, product dosage, manufacturing processes, safety and/or other matters, including decisions relating to emerging developments regarding potential product impurities; uncertainties regarding the ability to obtain, and the scope of, recommendations by technical or advisory committees; and the timing of, and ability to obtain, pricing approvals and product launches, all of which could impact the availability or commercial potential of our products and product candidates;
•claims and concerns that may arise regarding the safety or efficacy of in-line products and product candidates, including claims and concerns that may arise from the outcome of post-approval clinical trials, which could impact marketing approval, product labeling, and/or availability or commercial potential;
•the success and impact of external business development activities, such as the recent acquisition of Seagen, including the ability to identify and execute on potential business development opportunities; the ability to satisfy the conditions to closing of announced transactions in the anticipated time frame or at all; the ability to realize the anticipated benefits of any such transactions in the anticipated time frame or at all; the potential need for and impact of additional equity or debt financing to pursue these opportunities, which could result in increased leverage and/or a further downgrade of our credit ratings; challenges integrating the businesses and operations; disruption to business and operations relationships; risks related to growing revenues for certain acquired or partnered products; significant transaction costs; and unknown liabilities;
•competition, including from new product entrants, in-line branded products, generic products, private label products, biosimilars and product candidates that treat or prevent diseases and conditions similar to those treated or intended to be prevented by our in-line products and product candidates;
•the ability to successfully market both new and existing products, including biosimilars;
- 28 -
•difficulties or delays in manufacturing, sales or marketing; supply disruptions, shortages or stock-outs at our facilities or third-party facilities that we rely on; and legal or regulatory actions;
•the impact of public health outbreaks, epidemics or pandemics (such as COVID-19) on our business, operations and financial condition and results, including impacts on our employees, manufacturing, supply chain, sales and marketing, R&D and clinical trials;
•risks and uncertainties related to our efforts to develop and commercialize our COVID-19 products, as well as challenges related to their manufacturing, supply and distribution, including, among others, the risk that as the market for COVID-19 products becomes more endemic and seasonal, demand for any of our COVID-19 products has and may continue to be reduced or not meet expectations, or may no longer exist, which has and may continue to lead to reduced revenues, excess inventory on-hand and/or in the channel which, for Paxlovid and Comirnaty, has resulted in significant inventory write-offs in 2023 and could continue to result in inventory write-offs or other unanticipated charges; challenges related to the transition to the commercial market for our COVID-19 products; uncertainties related to the public’s demand for vaccines, boosters and COVID-19 treatments; risks related to our ability to accurately forecast and achieve our revenue forecasts for Comirnaty and Paxlovid or any potential future COVID-19 vaccines or treatments; uncertainties inherent in R&D, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for clinical trials, regulatory submission dates, regulatory approval dates and/or launch dates, as well as risks associated with pre-clinical and clinical data (including Phase 1/2/3 or Phase 4 data for Comirnaty or any vaccine candidate in the BNT162 program or Paxlovid or any future COVID-19 treatment) in any of our studies in pediatrics, adolescents or adults or real world evidence, including the possibility of unfavorable new pre-clinical, clinical or safety data and further analyses of existing pre-clinical, clinical or safety data or further information regarding the quality of pre-clinical, clinical or safety data, including by audit or inspection; the ability to produce comparable clinical or other results for Comirnaty, any vaccine candidate or other vaccines that may result from the BNT162 program, Paxlovid or any future COVID-19 treatment or any other COVID-19 program, including the rate of effectiveness and/or efficacy, safety and tolerability profile observed to date, in additional analyses of the Phase 3 trial for any such products and additional studies, in real-world data studies or in larger, more diverse populations following commercialization; the ability of Comirnaty or any future vaccine to prevent, or Paxlovid or any future COVID-19 treatment to be effective against, COVID-19 caused by emerging virus variants; the risk that use of Comirnaty or Paxlovid will lead to new information about efficacy, safety or other developments, including the risk of additional adverse reactions, some of which may be serious; the risk that pre-clinical and clinical trial data are subject to differing interpretations and assessments, including during the peer review/publication process, in the scientific community generally, and by regulatory authorities; whether and when additional data from the BNT162 program, Paxlovid or other COVID-19 programs will be published in scientific journal publications and, if so, when and with what modifications and interpretations; whether regulatory authorities will be satisfied with the design of and results from existing or future pre-clinical and clinical studies; whether and when submissions to request emergency use or conditional marketing authorizations for Comirnaty or any future vaccines in additional populations, for a potential booster dose for Comirnaty, or any potential future vaccine or vaccine candidates (including potential future annual boosters or re-vaccinations), and/or biologics license and/or EUA applications or amendments to any such applications may be filed in particular jurisdictions for Comirnaty or any other potential vaccine or vaccine candidates, and if obtained, whether or when such EUA or licenses, or existing EUAs, will expire or terminate; whether and when submissions to request emergency use or conditional marketing authorizations for Paxlovid or any future COVID-19 treatment and/or any drug applications and/or EUA applications or amendments to any such applications for any indication for Paxlovid or any future COVID-19 treatment may be filed in particular jurisdictions, and if obtained, whether or when such EUA or licenses, or existing EUAs, will expire or terminate; whether and when any application that may be pending or filed for Comirnaty, any vaccine candidate or other vaccines that may result from the BNT162 program, Paxlovid or any future COVID-19 treatment or any other COVID-19 program may be approved by particular regulatory authorities, which will depend on myriad factors, including making a determination as to whether the vaccine’s or drug’s benefits outweigh its known risks and determination of the vaccine’s or drug’s efficacy and, if approved, whether it will be commercially successful; decisions by regulatory authorities impacting labeling or marketing, manufacturing processes, safety and/or other matters that could affect the availability or commercial potential of any vaccine or drug, including the authorization or approval of products or therapies developed by other companies; disruptions in the relationships between us and our collaboration partners, clinical trial sites or third-party suppliers, including our relationship with BioNTech; the risk that other companies may produce competitive products that may be superior in terms of efficacy, safety, affordability, convenience, or a number of other competitive factors; risks related to the availability or cost of raw materials to manufacture or test any such products; challenges related to our vaccine’s formulation and attendant storage, distribution and administration requirements, including risks related to storage and handling after delivery by us; challenges and risks related to medication errors such as prescribing or dispensing the wrong strength, improper dosing and self-administration errors; the risk that we may not be able to successfully develop other vaccine formulations, booster doses or potential future vaccines, potential combination respiratory vaccines or next generation COVID-19 treatments; the risk
- 29 -
that we may not be able to recoup costs associated with our R&D and manufacturing efforts; risks associated with any changes in the way we approach or provide research funding for the BNT162 program, Paxlovid or any other COVID-19 program; challenges and risks associated with the pace of our development programs; the risk that we may not be able to maintain manufacturing capacity or access to logistics or supply channels commensurate with global demand for our COVID-19 products, which would negatively impact our ability to supply our COVID-19 products within the projected time periods; whether and when additional supply or purchase agreements will be reached or existing agreements will be modified; uncertainties regarding the ability to obtain recommendations from vaccine or treatment advisory or technical committees and other public health authorities and uncertainties regarding the commercial impact of any such recommendations; pricing and access challenges for such products; challenges related to public confidence in, or awareness of Comirnaty, Paxlovid or any future COVID-19 product candidates, including challenges driven by misinformation or disinformation, access, concerns about clinical data integrity, or prescriber and pharmacy education; trade restrictions; potential third-party royalties or other claims related to Comirnaty or Paxlovid; and competitive developments;
•trends toward managed care and healthcare cost containment, and our ability to obtain or maintain timely or adequate pricing or favorable formulary placement for our products;
•interest rate and foreign currency exchange rate fluctuations, including the impact of currency devaluations and monetary policy actions in countries experiencing high inflation or deflation rates;
•any significant issues involving our largest wholesale distributors or government customers, which account for a substantial portion of our revenues;
•the impact of the increased presence of counterfeit medicines, vaccines or other products in the pharmaceutical supply chain;
•any significant issues related to the outsourcing of certain operational and staff functions to third parties;
•any significant issues related to our JVs and other third-party business arrangements, including modifications related to supply agreements or other contracts with customers including governments or other payors;
•uncertainties related to general economic, political, business, industry, regulatory and market conditions including, without limitation, uncertainties related to the impact on us, our customers, suppliers and lenders and counterparties to our foreign-exchange and interest-rate agreements of challenging global economic conditions, such as inflation or interest rate fluctuations, and recent and possible future changes in global financial markets;
•the exposure of our operations globally to possible capital and exchange controls, economic conditions, expropriation, sanctions and/or other restrictive government actions, changes in intellectual property legal protections and remedies, unstable governments and legal systems and inter-governmental disputes;
•the impact of disruptions related to climate change and natural disasters, including uncertainties related to the impact of the tornado at our manufacturing facility in Rocky Mount, NC in 2023;
•any changes in business, political and economic conditions due to actual or threatened terrorist activity, geopolitical instability, political or civil unrest or military action, including the ongoing conflicts between Russia and Ukraine and in the Middle East and the resulting economic or other consequences;
•the impact of product recalls, withdrawals and other unusual items, including uncertainties related to regulator-directed risk evaluations and assessments, including our ongoing evaluation of our product portfolio for the potential presence or formation of nitrosamines;
•trade buying patterns;
•the risk of an impairment charge related to our intangible assets, goodwill or equity-method investments;
•the impact of, and risks and uncertainties related to, restructurings and internal reorganizations, as well as any other corporate strategic initiatives and growth strategies, and cost-reduction and productivity initiatives, each of which requires upfront costs but may fail to yield anticipated benefits and may result in unexpected costs, organizational disruption, adverse effects on employee morale, retention issues or other unintended consequences;
•the ability to successfully achieve our climate goals and progress our environmental sustainability and other ESG priorities;
Risks Related to Government Regulation and Legal Proceedings:
•the impact of any U.S. healthcare reform or legislation or any significant spending reduction or cost control efforts affecting Medicare, Medicaid or other publicly funded or subsidized health programs, including the Inflation Reduction Act of 2022, or changes in the tax treatment of employer-sponsored health insurance that may be implemented;
•U.S. federal or state legislation or regulatory action and/or policy efforts affecting, among other things, pharmaceutical product pricing, intellectual property, reimbursement or access or restrictions on U.S. direct-to-consumer advertising;
- 30 -
limitations on interactions with healthcare professionals and other industry stakeholders; as well as pricing pressures for our products as a result of highly competitive biopharmaceutical markets;
•legislation or regulatory action in markets outside of the U.S., such as China or Europe, including, without limitation, laws related to pharmaceutical product pricing, intellectual property, medical regulation, environmental protections, reimbursement or access, including, in particular, continued government-mandated reductions in prices and access restrictions for certain biopharmaceutical products to control costs in those markets;
•legal defense costs, insurance expenses, settlement costs and contingencies, including without limitation, those related to actual or alleged environmental contamination;
•the risk and impact of an adverse decision or settlement and risk related to the adequacy of reserves related to legal proceedings;
•the risk and impact of tax related litigation and investigations;
•governmental laws and regulations affecting our operations, including, without limitation, the Inflation Reduction Act of 2022, changes in laws and regulations or their interpretation, including, among others, changes in tax laws and regulations internationally and in the U.S., the adoption of global minimum taxation requirements outside the U.S. generally effective in most jurisdictions since January 1, 2024 and potential changes to existing tax law by the current U.S. Presidential administration and Congress, including the proposed “Tax Relief for American Families and Workers Act of 2024”;
Risks Related to Intellectual Property, Technology and Security:
•any significant breakdown or interruption of our information technology systems and infrastructure (including cloud services);
•any business disruption, theft of confidential or proprietary information, security threats on facilities or infrastructure, extortion or integrity compromise resulting from a cyber-attack or other malfeasance by, but not limited to, nation states, employees, business partners or others;
•risks and challenges related to the use of artificial intelligence-based software;
•the risk that our currently pending or future patent applications may not be granted on a timely basis or at all, or any patent-term extensions that we seek may not be granted on a timely basis, if at all; and
•risks to our products, patents and other intellectual property, such as: (i) claims of invalidity that could result in loss of exclusivity; (ii) claims of patent infringement, including asserted and/or unasserted intellectual property claims; (iii) claims we may assert against intellectual property rights held by third parties; (iv) challenges faced by our collaboration or licensing partners to the validity of their patent rights; or (v) any pressure, or legal or regulatory action by, various stakeholders or governments that could potentially result in us not seeking intellectual property protection or agreeing not to enforce or being restricted from enforcing intellectual property rights related to our products, including Comirnaty and Paxlovid.
Should known or unknown risks or uncertainties materialize or should underlying assumptions prove inaccurate, actual results could vary materially from past results and those anticipated, estimated or projected. Investors are cautioned not to put undue reliance on forward-looking statements. A further list and description of risks, uncertainties and other matters can be found in our Annual Report on Form 10-K for the fiscal year ended December 31, 2022 and in our subsequent reports on Form 10-Q, in each case including in the sections thereof captioned “Forward-Looking Information and Factors That May Affect Future Results” and “Item 1A. Risk Factors,” and in our subsequent reports on Form 8-K.
This earnings release may include discussion of certain clinical studies relating to various in-line products and/or product candidates. These studies typically are part of a larger body of clinical data relating to such products or product candidates, and the discussion herein should be considered in the context of the larger body of data. In addition, clinical trial data are subject to differing interpretations, and, even when we view data as sufficient to support the safety and/or effectiveness of a product candidate or a new indication for an in-line product, regulatory authorities may not share our views and may require additional data or may deny approval altogether.
The information contained on our website or any third-party website is not incorporated by reference into this earnings release. All trademarks mentioned are the property of their owners.
- 31 -